

Review

Not peer-reviewed version

Aggregatibacter actinomycetemcomitans Dispersin B: The Quintessential Antibiofilm Enzyme

[Jeffrey B. Kaplan](#)*, [Svetlana A. Sukhishvili](#), Milosavljević Sailer, [Khalaf Kridin](#), Narayanan Ramasubbu

Posted Date: 23 July 2024

doi: 10.20944/preprints202407.1788.v1

Keywords: biofilm matrix; biomaterial coating; DspB; EPS; exopolysaccharide; extracellular DNA; eDNA; matrix-degrading enzyme; PIA; PNAG; *Staphylococcus aureus*; *Staphylococcus*



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Review

Aggregatibacter actinomycetemcomitans Dispersin B: The Quintessential Antibiofilm Enzyme

Jeffrey B. Kaplan ^{1,*}, Svetlana A. Sukhishvili ², Miloslav Sailer ³, Khalaf Kridin ^{1,4} and Narayanan Ramasubbu ⁵

¹ Laboratory for Skin Research, Institute for Medical Research, Galilee Medical Center, Nahariya 2210001, Israel

² Department of Materials Science and Engineering, Texas A&M University, College Station, Texas 77843, USA

³ Kane Biotech Inc., Winnipeg, Manitoba R3T 6G2, Canada

⁴ The Azrieli Faculty of Medicine, Bar-Ilan University, Safed 1311502, Israel

⁵ Department of Oral Biology, Rutgers School of Dental Medicine, Newark, New Jersey 07103, USA

* Correspondence: kaplanjb@american.edu

Abstract: The extracellular matrix of most bacterial biofilms contains polysaccharides, proteins, and nucleic acids. These biopolymers have been shown to mediate fundamental biofilm-related phenotypes including surface attachment, intercellular adhesion, and biocide resistance. Enzymes that degrade polymeric biofilm matrix components, including glycoside hydrolases, proteases, and nucleases, are useful tools for studying the structure and function of biofilm matrix components and are also being investigated as potential antibiofilm agents for clinical use. Dispersin B is a well-studied, broad spectrum antibiofilm glycoside hydrolase produced by *Aggregatibacter actinomycetemcomitans*. Dispersin B degrades poly-*N*-acetylglucosamine, a biofilm matrix polysaccharide that mediates biofilm formation, stress tolerance, and biocide resistance in numerous Gram-negative and Gram-positive pathogens. Dispersin B has been shown to inhibit biofilm and pellicle formation; detach pre-formed biofilms; disaggregate bacterial flocs; sensitize pre-formed biofilms to detachment by enzymes, detergents, and metal chelators; and sensitize pre-formed biofilms to killing by antiseptics, antibiotics, bacteriophages, macrophages, and predatory bacteria. This review summarizes the results of nearly 100 in vitro and in vivo studies that have been carried out on dispersin B since its discovery 20 years ago. These include investigations into the biological function of the enzyme, its structure and mechanism of action, and its in vitro and in vivo antibiofilm activities against numerous bacterial species. Also discussed are potential clinical applications of dispersin B.

Keywords: biofilm matrix; biomaterial coating; DspB; EPS; exopolysaccharide; extracellular DNA; eDNA; matrix-degrading enzyme; PIA; PNAG; *Staphylococcus aureus*; *Staphylococcus*

1. Introduction

Biofilms are densely packed communities of microorganisms, enclosed in a self-synthesized extracellular polymeric matrix, growing attached to a tissue or surface [1]. Biofilm is the primary mode of growth for microbes in most natural, industrial, and clinical environments. Biofilms exhibit a high tolerance to exogenous stress, and treatment of biofilms with biocides is usually ineffective at eradicating them [2]. Biofilms create many problems ranging from industrial corrosion and biofouling to chronic and nosocomial infections.

Various antibiofilm strategies are currently being investigated. These include biomaterial surface modifications, quorum sensing inhibitors, quorum quenching enzymes, bacteriophages and phage-derived enzymes, and biofilm matrix-degrading enzymes [3]. The biofilm matrix is a good target for antibiofilm agents because unlike cells buried deep within the biofilm colony, the biofilm

matrix is highly accessible to the outside environment and inherently porous [4]. Agents that degrade or destabilize the biofilm matrix could inhibit biofilm formation or promote detachment of established biofilm colonies [3]. Once the biofilm colony is dispersed, the cells exhibit increased sensitivity to killing by biocides and host defenses.

Numerous biofilm matrix-degrading enzymes have been described [5–7]. These include various glycoside hydrolases, proteases, and nucleases which degrade polysaccharide, protein, and nucleic acid component of the biofilm matrix, respectively. These biopolymers have been shown to mediate fundamental biofilm-related phenotypes including surface attachment, intercellular adhesion, and biocide resistance [4]. The advantages of biofilm matrix-degrading enzymes are that they exhibit broad spectrum activity, and they exert little or no selection pressure because they generally do not kill bacteria or inhibit their growth. The disadvantage of these enzymes is that they release microbial cells from the biofilm that could spread and cause infections at distant sites or elicit a hyper-inflammatory or hyper-immunogenic response [6]. Therefore, biofilm matrix-degrading enzymes may be more useful for biofilm prevention rather than for treatment of established biofilms, or may need to be used in combination with antimicrobial agents to minimize these risks.

The glycoside hydrolase dispersin B is one of the best studied biofilm matrix-degrading enzymes. Dispersin B hydrolyzes poly-N-acetylglucosamine (PNAG), a biofilm matrix polysaccharide that plays a role in surface attachment, biofilm formation, and biocide resistance in a wide range of Gram-negative and Gram-positive pathogens [8]. This review describes the initial discovery and characterization of dispersin B from *Aggregatibacter actinomycetemcomitans* as well as subsequent studies on its structure and mechanism of action. Also highlighted are numerous studies demonstrating that dispersin B exhibits broad spectrum antibiofilm activity against more than 25 phylogenetically diverse bacterial species in vitro and in vivo. Some potential clinical applications of dispersin B such medical device coatings, topical wound gels and combination products will also be discussed.

2. Discovery of Dispersin B

The Gram-negative, non-motile oral pathogen *A. actinomycetemcomitans* forms extremely tenacious biofilms on abiotic surfaces such as plastic and glass in vitro [9]. Its adherence is so strong that the broth shows no turbidity, removal of cells from the culture vessel surface by vortex agitation is negligible, and aliquots of medium taken from the culture are often sterile upon subculture. This remarkable phenotype makes *A. actinomycetemcomitans* a useful model for studying the process of biofilm dispersal because cells that detach from mature biofilm colonies adhere tightly to the surface of the culture vessel and form independent daughter biofilm colonies that can be visualized and enumerated (Figure 1, left panel). Screening a transposon mutant library of *A. actinomycetemcomitans* strain CU1000 identified five mutant strains that were defective in biofilm dispersal (Figure 1, right panel). The transposons in three mutant strains inserted into genes required for lipopolysaccharide O-side-chain biosynthesis [10], the transposon in one mutant strain inserted into *ptsI*, which encodes a regulator of sugar uptake and catabolite repression (J.B. Kaplan, unpublished results), and the transposon in one mutant strain (designated JK1023) inserted into a novel gene encoding a putative β -hexosaminidase enzyme [11]. The gene disrupted in mutant strain JK1023 was named *dspB* and the protein it encodes was named dispersin B. A plasmid carrying a wild-type *dspB* gene restored the ability of JK1023 biofilm colonies to disperse [11].




Figure 1. Dispersal of isolated *Aggregatibacter actinomycetemcomitans* biofilm colonies growing on the surface of polystyrene Petri dishes. Left panel, wild-type strain CU1000; right panel, $\Delta dspB$ mutant strain JK1023. Satellite colonies surrounding the dispersed CU1000 biofilm colony were absent in the JK1023 culture. Photos were taken 3 d after inoculation. Measure bar = 1 mm. Image from [127].

3. Biological Functions of Dispersin B

Although *A. actinomycetemcomitans* $\Delta dspB$ mutant strain JK1023 exhibited a severe biofilm dispersal defect in broth, it exhibited wild-type surface attachment and biofilm formation phenotypes (Figure 1). Strain JK1023 also produced colonies on agar that had a hard texture and were extremely difficult to remove from the agar surface. In test tubes, JK1023 cells aggregated and settled to the bottom of the tube much more rapidly than cells of wild-type strain CU1000 [11]. These phenotypes demonstrate that dispersin B decreases *A. actinomycetemcomitans* intercellular adhesion in vitro. Stacy et al. [12] constructed a $\Delta dspB$ mutation in a different *A. actinomycetemcomitans* parental strain (strain 624). They confirmed that dispersin B promotes biofilm dispersal in vitro and further demonstrated that dispersin B-mediated biofilm dispersal is triggered by oxygen and H₂O₂. In a murine abscess model, the *A. actinomycetemcomitans* 624 $\Delta dspB$ mutant strain established similar single-species infections compared to the wild-type strain, but upon co-infection with *Streptococcus gordonii*, the 624 $\Delta dspB$ mutant strain formed larger cell aggregates than those formed by wild-type strain, and these aggregates were located closer to *S. gordonii* aggregates than those of the wild-type strain. These findings suggest that dispersin B can modulate the spatial organization of cells within multi-species biofilms in vivo.

Zhang et al. [13] constructed a $\Delta dspB$ mutation in *Actinobacillus pleuropneumoniae* strain 4074, a swine pathogen that produces an orthologue of *A. actinomycetemcomitans* dispersin B [14]. The *A. pleuropneumoniae* $\Delta dspB$ mutant strain exhibited increased autoaggregation and biofilm formation in vitro, phenotypes that were not evident when a wild-type $\Delta dspB$ gene was supplied on a plasmid. These findings confirm that dispersin B modulates bacterial intercellular adhesion and biofilm formation in different species in vitro.

4. The $\Delta dspB$ Gene

The *A. actinomycetemcomitans* $\Delta dspB$ gene encodes a protein of 381 amino acids which includes a 20 amino acid N-terminal signal sequence that is cleaved upon secretion outside the cell. The genomes of at least 32 different bacterial species contain homologues of *A. actinomycetemcomitans* $\Delta dspB$ (Table 1 and Figure 2). These include 16 species of Pasteurellaceae, 15 species of Neisseriaceae, and *Cardiobacterium hominis* (family Cardiobacteriaceae). Pasteurellaceae and Neisseriaceae have been found on the mucosal surfaces of the upper respiratory tract of vertebrates and are often opportunistic pathogens [15]. *C. hominis* is a normal human oral and upper respiratory commensal that is rarely a cause of endocarditis [16]. The phylogeny of $\Delta dspB$ homologues was congruent with the phylogenetic tree at the species level (Figure 2), suggesting that $\Delta dspB$ emerged in an ancestor of

these three bacterial families. All the amino acid residues that play a critical role in *A. actinomycetemcomitans* dispersin B substrate hydrolysis (Arg27, Asp183, Glu184, Glu332; see below), as well as the three tryptophan residues at positions 216, 237, and 330 that line part of the substrate-binding pocket, are conserved in 31 of the 32 dspB homologues analyzed. Only the *Kingella oralis* homologue has substitutions at these critical positions (Arg27His, Glu184Ala, Trp237His, Trp330Glu, Glu332Asp). This suggests that most dspB homologues have the potential to encode functional dispersin B enzymes. Differences in the lengths of the predicted proteins result from N- or C-terminal extensions in the sequence of some species. Only small insertions/deletions of 1-4 amino acids are present within the core region of the protein.

Table 1. Homologues of *A. actinomycetemcomitans* dspB in bacteria.

Species	Family	GenBank Accession No.	Amino acids
<i>Actinobacillus capsulatus</i>	<i>Pasteurellaceae</i>	WP_018652103.1	378
<i>Actinobacillus equuli</i>	<i>Pasteurellaceae</i>	WP_039197353.1	378
<i>Actinobacillus lignieresii</i>	<i>Pasteurellaceae</i>	WP_126375001.1	377
<i>Actinobacillus pleuropneumoniae</i>	<i>Pasteurellaceae</i>	WP_005617581.1	377
<i>Actinobacillus succinogenes</i>	<i>Pasteurellaceae</i>	WP_012072607	508
<i>Actinobacillus suis</i>	<i>Pasteurellaceae</i>	WP_014991875.1	378
<i>Actinobacillus ureae</i>	<i>Pasteurellaceae</i>	WP_115607612.1	378
<i>Actinobacillus vicugnae</i>	<i>Pasteurellaceae</i>	WP_150540037.1	378
<i>Aggregatibacter actinomycetemcomitans</i>	<i>Pasteurellaceae</i>	WP_005566076	361
<i>Aggregatibacter aphrophilus</i>	<i>Pasteurellaceae</i>	OPY54997.1	403
<i>Aggregatibacter kilianii</i>	<i>Pasteurellaceae</i>	WP_275425143.1	339
<i>Basfia succiniciproducens</i>	<i>Pasteurellaceae</i>	WP_305367133	480
<i>Cardiobacterium hominis</i>	<i>Cardiobacteriaceae</i>	WP_281839854.1	528
<i>Exercitatus varius</i>	<i>Pasteurellaceae</i>	WP_317543108.1	508
<i>Haemophilus pittmaniae</i>	<i>Pasteurellaceae</i>	WP_269457014	381
<i>Kingella oralis</i>	<i>Neisseriaceae</i>	WP_315367803.1	405
<i>Lonepinella koalarum</i>	<i>Pasteurellaceae</i>	WP_228777406.1	363
<i>Mannheimia succiniciproducens</i>	<i>Pasteurellaceae</i>	AAU37718.1	501
<i>Neisseria animaloris</i>	<i>Neisseriaceae</i>	WP_199901419.1	517
<i>Neisseria brasiliensis</i>	<i>Neisseriaceae</i>	MRN37458.1	340
<i>Neisseria canis</i>	<i>Neisseriaceae</i>	WP_085415444.1	508
<i>Neisseria chentwenguii</i>	<i>Neisseriaceae</i>	WP_199720929.1	421
<i>Neisseria dentiae</i>	<i>Neisseriaceae</i>	WP_211276428.1	400
<i>Neisseria dumasiana</i>	<i>Neisseriaceae</i>	WP_085417823.1	395
<i>Neisseria montereyensis</i>	<i>Neisseriaceae</i>	WP_289623084.1	398
<i>Neisseria musculi</i>	<i>Neisseriaceae</i>	WP_187000616.1	388
<i>Neisseria oralis</i>	<i>Neisseriaceae</i>	WP_308022698.1	410
<i>Neisseria shayegani</i>	<i>Neisseriaceae</i>	WP_220457298.1	770
<i>Neisseria wadsworthii</i>	<i>Neisseriaceae</i>	WP_009115775.1	468
<i>Neisseria weixii</i>	<i>Neisseriaceae</i>	WP_096294699.1	392
<i>Neisseria zalophi</i>	<i>Neisseriaceae</i>	WP_318527728.1	398
<i>Neisseria zoodegmatis</i>	<i>Neisseriaceae</i>	WP_085364538.1	395




Figure 2. Phylogenetic relatedness dispersin B homologues based on pairwise alignments of amino acid sequences. The tree diagram was generated using ClustalW. GenBank accession numbers of the sequences are listed in Table 1. Horizontal branch lengths are proportional to the number of amino acid differences in the pairwise alignments. Bacterial families are indicated at the right.

Several studies investigated transcriptional regulation of *A. actinomycetemcomitans* *dspB*, which is flanked by an upstream promoter sequence and a downstream rho-independent transcription terminator sequence and does not appear to be part of an operon. Stacy et al. [17] analyzed the transcriptome of *A. actinomycetemcomitans* strain VT1169 during oxic and anoxic growth using DNA microarrays. They found that *dspB* transcription was induced by oxygen. They also cloned the *dspB* promoter upstream of a *lacZ* reporter gene and then introduced the *dspB-lacZ* reporter gene into *A. actinomycetemcomitans* strains 624 and VT1169. When grown as colony biofilms, both reporter strains exhibited significant β -galactosidase activity under oxic conditions but little activity under anoxic conditions. Interestingly, *dspB* induction in both strains could be mitigated by exogenously added catalase or a mutation *oxyR* which encodes a transcriptional regulator. These findings indicate that *dspB* transcription is activated during growth with oxygen in an OxyR-dependent manner, and that the activating factor is likely H₂O₂. Using these same two *dspB-lacZ* reporter strains, Stacy et al. [17] showed that transcription of *dspB* was increased >5 fold upon iron restriction. This induction was abolished when FeSO₄ was added to the medium. Furthermore, *dspB* transcription was increased >30-fold in a Δfur mutant under the same conditions, confirming that the *dspB* promoter is regulated by iron and Fur.

Ishikawa et al. [18] measured transcription of *dspB* in *A. actinomycetemcomitans* strain JP2 when cultured in the presence of conditioned media of three *Lactobacillus* spp. strains (*L. rhamnosus* LR32, *L. rhamnosus* HN001, *L. acidophilus* NCFM). Transcription of *dspB* was abrogated by LR32 and NCFM conditioned media but increased by HN001 medium. Similarly, Shakya et al. [19] found that *dspB* expression in *A. actinomycetemcomitans* strain ATTC 29523 was downregulated in

response to 3-phenyllactic acid, a compound produced by several medicinal plant extracts after fermentation with plant-derived strains of *Lactiplantibacillus plantarum* and *Pediococcus pentosaceus*. These findings suggest that lactic acid bacteria produce postbiotic compounds that can regulate *A. actinomycetemcomitans* biofilm formation through modulation of *dspB* expression.

5. Production of Recombinant Dispersin B in *Escherichia coli*

Kaplan et al. [11] constructed a plasmid (pRC1) which carries a gene encoding amino acids 21-381 of *A. actinomycetemcomitans* CU1000 dispersin B fused to a 32 amino acid C-terminal tail containing a hexahistidine metal binding site and a thrombin protease cleavage site that can be used to cleave the C-terminal tail from the hybrid protein. This gene was located downstream from an IPTG-inducible *tac* promoter. *E. coli* strain BL21(DE3) was transformed with pRC1, induced with IPTG, and the protein was purified using Ni²⁺-affinity chromatography. After cleavage with thrombin, the purified protein migrated with the expected molecular mass of 41.5 kDa. The yield of purified dispersin B was 10 mg/L of culture. Ramasubbu et al. [20] constructed a similar plasmid (pRC3) which encodes amino acids 21-381 of CU1000 *dspB* fused directly to a hexahistidine metal-binding C-terminal tail to facilitate crystallization. When expressed from an IPTG-inducible *tac* promoter on a plasmid and purified by Ni²⁺-affinity chromatography, this construct yielded up to 60 mg/L of dispersin B. Yakamdawala et al. [21] engineered a *dspB* gene devoid of the trinucleotide ACA. Previous studies showed that mRNA transcripts lacking ACA sequences are protected from degradation by MazF, a sequence-specific endoribonuclease produced by *E. coli*. Expression and purification of ACA-less *dspB* in *E. coli* strain Tuner(DE3)pLacI generated 236 mg/L of dispersin B versus 133 mg/L for wild-type *dspB* when expressed from a T7 promoter. Gökçen et al. [22] reported a dispersin B yield of about 60 mg/L when a codon-optimized *dspB* gene was cloned downstream from a tetracycline promoter/operator, transformed into *E. coli*, induced with anhydrotetracycline, and purified by Ni²⁺-affinity chromatography. In addition, Zeng et al. [23] reported that hexahistidine-tagged dispersin B purified on Ni²⁺ ion-chelated magnetic nanoparticles exhibited higher purity and activity than protein purified on conventional Ni²⁺-affinity columns.

6. Production of Recombinant Dispersin B in Tobacco

Tobacco expression systems offer several advantages over *E. coli* including lower costs, higher yields, and simplified downstream processing. Opdensteinen [24] expressed a codon optimized, hexahistidine-tagged *A. actinomycetemcomitans* *dspB* gene in *Nicotiana tabacum* BY2 cells and *N. benthamiana* plants. *N. benthamiana* is a close relative *N. tabacum* that is commonly used for “pharming” of recombinant proteins for clinical use. The recovery of dispersin B in planta was 75%, its purity was 96%, and a yield of up to 164 mg/kg of plant tissue was reported. These values were equivalent to those achieved in *E. coli*, suggesting that scalable purification of dispersin B in tobacco is feasible.

7. Dispersin B Structure and Mechanism of Action

A. actinomycetemcomitans dispersin B was crystalized using the hanging drop, vapor diffusion technique, and its 3D structure in complex with a glycerol molecule and an acetate ion at the active site was solved and refined to a resolution of 2.0 Å using the automated structure solution pipeline autoSHARP [20]. Dispersin B is a monomeric enzyme whose primary amino acid structure corresponds to that of the family 20 glycoside hydrolases. This family comprises diverse β-hexosaminidases produced by both prokaryotes and eukaryotes, as well as lacto-N-biosidase (EC 3.2.1.14), an enzyme involved in the degradation of human milk oligosaccharides in the gut microbiota of breast-fed infants.

Like all family 20 glycoside hydrolases, dispersin B adopts a TIM barrel protein fold consisting of eight α-helices and eight parallel β-strands that alternate along the polypeptide backbone (Figure 3). The active site of the enzyme is a large central cavity at the center of the TIM barrel which exhibits a negative electrostatic potential due to the presence of a number of polar acidic residues that are also

conserved in other β -hexosaminidases (Figure 4A). Trp216 and Trp330 form the floor of the 12 Å-deep substrate binding pocket where the hexose ring binds. Asp183 and Glu184 are the catalytic residues which are conserved in all family 20 glycoside hydrolases [25–27].




Figure 3. Ribbon diagram of *A. actinomycetemcomitans* dispersin B. α -helices are colored red and green. β -strands are colored blue.




Figure 4. Dispersin B active site and mechanism of action. (A) Electrostatic surface potential at the active site showing the negatively charged amino acids (Asp56, Asp183, Glu184, Glu332) which create a shallow anionic region in the catalytic pocket. The size of the pocket is approximately 12 Å. GOL, glycerol; ACY, acetate. Figure generated using ChimeraX [128]. (B) Substrate hydrolysis mechanism proposed for dispersin B and other family 20 hexosaminidases. In this substrate-assisted mechanism,

Glu184 acts as the acid/base. The nucleophile is the N-acetyl group of the substrate which is assisted by Asp183. Both exo- (dPNAG) and endoglycosidic (PNAG) cleavage are shown, where the leaving group is either deacetylated or acetylated, respectively. A suitably positioned Asp183 helps stabilize the oxazolium ion in the transition state. Figure generated using ChemDraw (PerkinElmer).

Evidence suggests that dispersin B utilizes a substrate-assisted mechanism, commonly referred to as the double displacement retaining mechanism, similar to other β -hexosaminidases (Figure 4B). A unique feature of this mechanism is the participation of the acetamido group of the substrate which provides anchimeric assistance and acts as the nucleophile while a suitably juxtaposed amino acid residue acts as the acid/base. This mechanism was confirmed using biochemical analyses of native dispersin B enzyme with different substrates, and mutational analyses [26,28–32]. In this mechanism, the active site residue Asp183 binds to the N-acetyl group of PNAG, and Glu184 serves as the catalytic acid/base (Figure 4B). Asp183 may also help stabilize the positive charge that develops in the oxazoline transition state (Figure 4B) or help distort the substrate to direct the 2-acetamido group toward the anomeric carbon [27]. Proteins with Asp183Asn and Glu184Gln mutations exhibited >10,000-fold and >70-fold decreased activity, respectively, compared to the wild-type enzyme irrespective of the substrate used for hydrolysis. A mutation in another acidic residue located near the catalytic residues (Glu332) exhibited 2,000-fold lower activity than the native enzyme. Glu332 may provide stabilization in the transition state while the terminal glucosamine is undergoing conformational changes [26]. Mutations in Asp147 and Asp245, which are also located in the anionic pocket near the active site, also exhibited decreased enzyme activity. These residues may play a role in recognition of the cationic PNAG substrate. Four aromatic amino acid residues (Tyr187, Tyr278, Trp237, Trp330) line the hydrophobic substrate binding pocket where they bind to and orient the PNAG substrate. As expected, mutations in these residues exhibited 5-2,400-fold less activity than the wild-type enzyme. In addition to these acidic and aromatic amino acid residues, all β -hexosaminidases have a conserved arginine involved in substrate binding at the active site, equivalent to Arg27 of *A. actinomycetemcomitans* dispersin B. Enzymes with Arg27Lys and Arg27Ala mutation exhibited 2,400-fold and a >1,700-fold reduction in activity. Overall, these mutational studies confirm that dispersin B utilizes the same substrate-assisted mechanism as that utilized by other family 20 glycosidase hydrolase enzymes.

All PNAG exopolysaccharides have been shown to be post-translationally modified by partial deacetylation (ca. 15-20%), which is critical for PNAG-dependent biofilm formation [8]. Dispersin B exhibits both exo- and endoglycosidase activity against PNAG depending on the nature of the substrate [26,29,30,33]. Dispersin B exhibits greater activity against deacetylated PNAG (dPNAG) than against fully-acetylated PNAG. Thus, the mechanism of action of dispersin B evidently depends on different patterns of deacetylation [33,34]. Studies utilizing site-directed mutagenesis and synthetic PNAG oligosaccharides demonstrated that the increased rate of hydrolysis for dPNAG was mediated by interaction of the glucosamine residues of dPNAG with Asp147 and Asp242, which are located in a shallow anionic groove adjacent to the catalytic pocket [34,35]. Dispersin B containing an Asp242Asn mutation was highly deficient in endoglycosidase activity while maintaining exoglycosidase activity. These findings suggest that dispersin B exhibits endoglycosidic cleavage against dPNAG due to the absence of an acetamido group on dPNAG. The exhibition of both exo- and endoglycosidic activity by dispersin B might be critical during biofilm formation and dispersal since this would catalyze the hydrolysis of both PNAG and dPNAG in an efficient manner.

8. Chemical Modification of Dispersin B

Abdelkader et al. [36] covalently modified dispersin B with nine cyclodextrin molecules. Cyclodextrins are cone-shaped molecules that contain a hydrophobic central cavity that can bind to other hydrophobic molecules. The cyclodextrin modifications had no effect on the ability of dispersin B to detach pre-formed biofilms produced by four strains of *S. epidermidis*. The researchers then covalently linked ciprofloxacin to a hydrophobic adamantyl group and formed a complex between dispersin B/cyclodextrin and ciprofloxacin/adamantane to create an “all-in-one” drug delivery

system that can destroy the biofilm matrix and simultaneously release the antibiotic. When tested against 24-h-old biofilms produced by *S. epidermidis* strain 5, a PNAG-overproducing strain, in 96-well microtiter plates, the enzyme/antibiotic complex exhibited more than 2-log increase in biofilm eradication compared to dispersin B/cyclodextrin alone, thereby demonstrating the feasibility of this approach.

9. Dispersin B-Loaded Nanoparticles

Various nanobiotechnology-based approaches for eradicating bacterial biofilms including functionalized metallic nanoparticles are being investigated. To this end, Liu et al. [37] created a fusion protein between dispersin B and MagR, a protein involved in response to magnetism in *Drosophila melanogaster* which can be used as a fusion partner to functionally immobilize proteins on magnetic surfaces. MagR was fused to the C-terminus of dispersin B, expressed in *E. coli*, and purified by Ni²⁺-affinity chromatography. The dispersin B-MagR fusion protein was immobilized on Fe₃O₄/SiO₂ magnetic nanoparticles and tested for its ability to detach pre-formed biofilms produced by *Bacillus cereus*, *Staphylococcus aureus*, and one additional staphylococcal strain in 24-well microtiter plates. The authors found that Fe₃O₄/SiO₂ nanoparticles loaded with the dispersin B-MagR fusion protein detached pre-biofilms more efficiently than Fe₃O₄/SiO₂ nanoparticles or dispersin B-MagR fusion protein alone. In addition, immobilization of dispersin B-MagR on magnetic nanoparticles increased the stability of the enzyme and increased its optimum temperature from 30°C to 37°C. Theoretically, this system could be used to deliver dispersin B to specific sites under the function of a magnetic force. Similarly, Chen & Lee [38] fused a 12 amino acid silver-binding peptide to the N-terminus of dispersin B in order to prepare Ag nanoparticle conjugated with dispersin B. The goal was to create an agent that could both disrupt biofilms and simultaneously kill planktonic cells released from the disrupted biofilms. Although Ag nanoparticle could not be conjugated with the dispersin B/Ag-binding peptide fusion protein because dispersin B precipitated in the presence of Ag ions, the fusion protein itself was found to detach pre-formed *S. epidermidis* biofilms grown on silicone sheets or glass cover slips two-fold more efficiently than native dispersin B.

10. Dispersin B-Expressing Bacteria as Therapeutic Agents

Several studies investigated the use of genetically engineered bacterial strains expressing dispersin B as live therapeutics against biofilm-related infections. Garrido et al. [39] constructed an attenuated strain of *Mycoplasma pneumoniae* which secretes both dispersin B and lysostaphin, an endopeptidase that cleaves the pentaglycine crossbridge of the staphylococcal cell wall. This engineered strain significantly reduced *S. aureus* biofilm formation in polystyrene microtiter plates and on polyurethane catheters in vitro, and in a murine catheter model in vivo. In addition, the engineered *M. pneumoniae* cells were significantly more efficient at inhibiting *S. aureus* biofilm formation than dispersin B alone or supernatants from the engineered strain, suggesting that such strains have the potential to provide a continuous supply of dispersin B at infection sites. Since *M. pneumoniae* is a respiratory pathogen, these engineered strains may be useful for the treatment of biofilm-associated respiratory infections.

Ghalsasi & Sourjik [40] fused the secretion tag from *E. coli* OmpA to the N-terminus of dispersin B and transformed the hybrid gene into *E. coli* strain W3110, thereby creating a “disrupter” strain that secretes dispersin B into the surrounding medium. When tested against pre-formed biofilms produced by *E. coli* strain TRMG1655 in 96-well microtiter plates, the disrupter strain was found to detach 50% of the target biofilm in 12 h when induced with 100 mM IPTG. Similarly, Ragunath et al. [41] displayed dispersin B on the surface of *E. coli* by fusing dispersin B to a 290 amino acid C-terminal region of *A. actinomycetemcomitans* Aae, an autotransporter protein involved in host cell binding. The C-terminal region of Aae inserts into the outer membrane and anchors the fusion partner in the membrane. *E. coli* cells that displayed dispersin B on their surface efficiently detached pre-formed *S. epidermidis* and *A. pleuropneumoniae* biofilms in a 96-well microtiter plate assay, further demonstrating the potential utility of this approach for biofilm control.

11. Dispersin B as a Probe for PNAG Production

PNAG has been identified as a conserved surface polysaccharide produced by diverse bacterial, fungal, and protozoal pathogens [42,43]. However, PNAG is difficult to isolate and purify because it is usually produced at low levels and is tightly bound to the cell surface. An alternative method for detecting PNAG is fluorescence confocal microscopy using the antigen-specific human IgG1 monoclonal antibody F598 [42]. Figure 5 shows that immunoreactivity of *Yersinia pestis* cells with mAb F598 was lost after the cells were treated with dispersin B but not with chitinase, a related glycoside hydrolase that does not degrade PNAG [44]. This same dispersin B-induced loss of immunoreactivity with mAb F598 was observed in *Bacillus subtilis* [45] and several other prokaryotic and eukaryotic pathogens [42,46,47]. These findings demonstrate that dispersin B can function as a sensitive and specific probe for PNAG.




Figure 5. Confocal microscopic analysis of PNAG expression by *Y. pestis* strain KIM6+ grown at 28°C overnight on Congo red agar. After treatment of bacterial cells with either chitinase (top panels) or dispersin B (bottom panels), cells were stained with Syto 83 to visualize DNA (red) and Alexa Fluor 488-conjugated mAb F598 to detect PNAG (green). Bars = 10 μ m. Figure from Yoong et al. [44].

Dispersin B is often used along with proteinase K and DNase I to investigate the composition of the biofilm matrix. For example, dispersin B, but not by proteinase K or DNase I, degraded insoluble extracellular matrix component of *S. aureus* strain SH1000 [48] and strain MR10 [49], confirming that the biofilm matrix of these strains contains primarily PNAG. This is consistent with the susceptibility the these strains to detachment by dispersin B.

Eddenden et al. [50] and Eddenden & Nitz [51] leveraged the specificity of dispersin B to construct a probe (Dispersin B PNAG probe or DiPP) for monitoring and localizing PNAG production during biofilm formation. DiPP was created by mutating one amino acid in the dispersin B active site (E184), which rendered the enzyme catalytically inactive but still capable of binding to PNAG, and then fusing inactive dispersin B to green fluorescent protein (GFP-DiPP). Fluorescent imaging studies demonstrated that GFP-DiPP bound to PNAG-dependent cells and biofilms but not to PNAG-independent cells and biofilms, thereby demonstrating the specificity of the probe for PNAG. DiPP binding experiments with PNAG-producing *E. coli* strain MG1655 revealed a high concentration of PNAG at the bacterial cell surface which was localized in discrete areas. These distinct areas appeared to slough from the cells and accumulate in interbacterial regions during the development of a PNAG-dependent biofilm. A helical distribution of staining was also observed, suggesting spatial organization of PNAG on the cell surface prior to biofilm formation. These

experiments demonstrate the potential value of a highly specific dispersin B probe for monitoring PNAG production.

12. Dispersin B as a Probe for PNAG Function

Several studies used dispersin B to demonstrate that PNAG plays a role in bacterial intercellular adhesion, biofilm formation, biofilm porosity, and host cell binding. Al Laham et al. [52] found that *S. epidermidis* small colony variants, which are sometimes associated with device infections, produced large cell aggregates when cultured under planktonic conditions. These cell aggregates were completely disintegrated by dispersin B, demonstrating that PNAG serves as an intercellular adhesin, a finding that was subsequently confirmed by indirect immunofluorescence assays with anti-PNAG antiserum. Similarly, Amini et al. [53] demonstrated that exogenously added PNAG enabled non-PNAG producing strains of *E. coli* to form biofilms, a fact that was confirmed when dispersin B treatment abolished the activity. Ganeshnarayanan et al. [54] measured transport of the antiseptic cetylpyridinium chloride (CPC) through *S. epidermidis* and *A. pleuropneumoniae* biofilms cultured in centrifugal filter devices. Significantly more CPC passed through the biofilms after treatment with dispersin B compared to the amount that passed through untreated biofilms, demonstrating that PNAG impedes transport of small molecules through biofilms. Similarly, Lin et al. [55] showed that pre-treating PNAG-expressing *S. carnosus* cells with dispersin B significantly decreased their ability to bind to human RPMI 2650 nasal epithelial cells.

13. Dispersin B as a Tool for eDNA Extraction

Extracellular DNA (eDNA) is an important matrix component of many bacterial biofilms, but it is sometimes difficult to isolate because it binds to other biofilm matrix components including PNAG [56]. Wu & Xi [57] showed that when biofilms of *Acinetobacter* sp. grown in 6-well microtiter plates were pre-treated with dispersin B, they yielded more eDNA than untreated biofilms. Similarly, Wu & Xi [58] showed that dispersin B treatment significantly increased the yield of eDNA extracted from *Stenotrophomonas maltophilia* and *Acinetobacter baylyi* AC811 biofilms grown in 6-well plates. Thus, dispersin B may be a useful tool for eDNA extraction and analysis.

14. Antibiofilm Activities of Dispersin B against Bacteria In Vitro

As outlined in Table 2, dispersin B exhibits various antibiofilm activities against more than 25 different species of Gram-negative and Gram-positive bacteria in vitro. These activities include (i) inhibition of biotic and abiotic surface attachment; (ii) inhibition of biofilm formation, (iii) detachment of pre-formed biofilms, (iv) inhibition of pellicle formation (biofilms at the air-liquid interface), (v) disaggregation of bacteria flocs (floating or suspended biofilms); (vi) sensitization of pre-formed biofilms to detachment by EDTA, SDS, proteinase K, DNase, and high velocity water irrigation, (vii) sensitization of biofilms to killing by antibiotics (ampicillin, cefamandole nafate, ciprofloxacin, clindamycin, rifampicin, tetracycline, tobramycin, vancomycin), antiseptics (benzoyl peroxide, cetylpyridinium chloride, SDS, triclosan), antimicrobial peptides (KSL-W, LL-37, polymyxin B), bacteriophages, human macrophages, and predatory *Bdellovibrio* bacteria; and (viii) inhibition of hyphal aggregation and surface adhesion in *Streptomyces* spp. Taken together, these findings confirm that PNAG plays a role in diverse biofilm-related functions, and that dispersin B exhibits broad spectrum antibiofilm activity.

Table 2. Antibiofilm activities of dispersin B against bacteria *in vitro*.

Species	Antibiofilm activity	References
<i>Achromobacter xylosoxidans</i>	Inhibits biofilm formation; detaches preformed biofilms.	[79]
<i>Acinetobacter baumannii</i>	Inhibits “pellicle” formation at the air-liquid interface, inhibits biofilm formation, detaches preformed biofilms,	[73,106]

	sensitizes pre-formed biofilms to killing by antimicrobial peptide KSL-W.	
<i>Actinobacillus pleuropneumoniae</i>	Inhibits biofilm formation; detaches preformed biofilms; sensitizes preformed biofilms to killing by ampicillin.	[14,54,107–113]
<i>Aggregatibacter actinomycetemcomitans</i>	Sensitizes planktonic cells to killing by human macrophages; sensitizes preformed biofilms to detachment by EDTA, SDS, proteinase K, and DNase; sensitizes preformed biofilms to killing by cetylpyridinium chloride and SDS; sensitizes preformed biofilms to killing by predatory <i>Bdellovibrio bacteriovorus</i> bacteria.	[60,114–116]
<i>Bordetella pertussis</i> , <i>B. parapertussis</i>	Inhibits biofilm formation, detaches pre-formed biofilms, sensitizes preformed biofilms to killing by antimicrobial peptides polymyxin B and LL-37.	[79,117,118,126]
<i>Burkholderia cepacia</i> complex	Inhibits biofilm formation; detaches preformed biofilms; sensitizes biofilms to killing by tobramycin.	[47,119]
<i>Corynebacterium striatum</i>	Detaches pre-formed biofilms.	[89]
<i>Cutibacterium acnes</i>	Inhibits surface attachment and biofilm formation; sensitizes biofilms to killing by benzoyl peroxide and tetracycline.	[59]
<i>Escherichia coli</i>	Inhibits biofilm formation; detaches preformed biofilms; sensitizes biofilms to killing by triclosan and bacteriophages.	[40,71,77,87,90,102]
<i>Francisella novicida</i> , <i>F. philomiragia</i>	Detaches preformed biofilms.	[120]
<i>Klebsiella pneumoniae</i>	Inhibits biofilm formation; sensitizes preformed biofilms to killing by antimicrobial peptide KSL-W.	[72,73]
<i>Pectobacterium atrosepticum</i> , <i>P. carotovorum</i>	Inhibits biofilm formation; detaches preformed biofilms.	[88,121]
<i>Pseudomonas fluorescens</i>	Inhibits biofilm formation; detaches preformed biofilms, inhibits attachment of planktonic cells to tomato roots.	[87]; J. B. Kaplan, unpublished data
<i>Ralstonia solanacearum</i>	Inhibits biofilm formation.	J. B. Kaplan, unpublished data
<i>Solobacterium moorei</i>	Inhibits biofilm formation.	[62]
<i>Staphylococcus aureus</i>	Inhibits biofilm formation, detaches preformed biofilms; sensitizes preformed biofilms to killing by triclosan, tobramycin, vancomycin, rifampicin, clindamycin, cefamandole nafate and antimicrobial peptide KSL-W.	[64,66–74,80,90,91]
<i>Staphylococcus capitis</i>	Detaches preformed biofilms.	[80]
<i>Staphylococcus epidermidis</i>	Inhibits biofilm formation; detaches preformed biofilms; sensitizes preformed biofilms to killing by triclosan, cetylpyridinium chloride, ciprofloxacin, rifampicin and antimicrobial peptide KSL-W.	[36,54,67,68,71–73,75–83,86,122]
<i>Staphylococcus pseudintermedius</i>	Inhibits biofilm formation; detaches preformed biofilms.	[123]
<i>Streptococcus mutans</i>	Detaches preformed biofilms; sensitizes preformed biofilms to detachment by oral irrigation.	[124]
<i>Streptomyces coelicolor</i> ,	Inhibits surface attachment and hyphal aggregation.	[125]

<i>S. lividans</i>		
<i>Xanthomonas citri</i>	Disaggregates bacterial flocs (floating or suspended biofilms).	J. B. Kaplan, unpublished data
<i>Yersinia pestis</i>	Inhibits biofilm formation.	[87]

Some studies have shown that the ability of dispersin B to inhibit biofilm formation and detach pre-formed biofilms depends on the shape, size, and composition of the culture vessel. For example, biofilm formation by *Cutibacterium acnes* was inhibited by dispersin B when biofilms were cultured in glass tubes but not when cultured in 96-well polystyrene microtiter plates [59]. Similarly, dispersin B efficiently detached *A. actinomycetemcomitans* biofilms cultured in polystyrene tubes but not in polystyrene microtiter plate wells [60]. These results may reflect differences in biofilm architecture or biofilm matrix composition resulting from differences in the culture vessel shape, culture volume, surface-to-volume ratio, or substrate material. In addition, some studies found that dispersin B treatment appears to increase biofilm formation when biofilm biomass is measured using a crystal violet binding assay. For example, Izano et al. [60] found that treatment of pre-formed *A. actinomycetemcomitans* biofilms cultured in 96-well polystyrene microtiter plates with dispersin B resulted in a significant increase in crystal violet binding compared to mock-treated biofilms. Similarly, Atwood et al. [61] found that biofilms formed by *S. aureus* rsbU and sigB mutant strains in microtiter plates bound significantly more crystal violet dye when they were cultured in dispersin B-supplemented broth compared to the amount of bound dye in unsupplemented broth. One possible explanation for these results is that dispersin B increases the volume and porosity of the biofilm matrix, thereby allowing more crystal violet dye molecules to enter the biofilm.

Numerous studies reported that dispersin B exhibits no bacteriostatic or bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria. These results are most often reported as “data not shown.” However, LeBel et al. [62] found that dispersin B exhibited dose-dependent growth inhibition of *Solobacterium moorei* in microtiter plate wells, with approximately 50% growth inhibition at 5-50 µg/mL dispersin B. Other studies showed that dispersin B was not cytotoxic against human HEP-2 larynx carcinoma cells, human HaCaT keratinocytes, human THP-1 monocytes, human MG-63 osteoblasts, murine J774 macrophages, murine L929 fibroblasts, or sheep erythrocytes [63–65].

15. Antibiofilm Activities of Dispersin B against *Staphylococcus aureus*

S. aureus has received considerable attention because it causes many serious biofilm-related infections and also forms PNAG-dependent biofilms. Nearly all *S. aureus* strains carry the *icaADBC* operon which encodes the enzymes required for PNAG biosynthesis [8]. However, only some strains appear to rely on PNAG expression for biofilm formation in vitro and in vivo. This fact is reflected in the varied responses of *S. aureus* biofilms to dispersin B treatment. For example, Hogan et al. [66] measured the ability of dispersin B to detach 24-h-old *S. aureus* biofilms grown in plasma-coated microtiter plate wells. They found that dispersin B at 0.125-4 µg/mL effectively detached biofilms formed by *S. aureus* strain SH1000, a methicillin-sensitive *S. aureus* (MSSA) strain, but not those formed by *S. aureus* strain JE2, a methicillin-resistant *S. aureus* (MRSA) strain. However, dispersin B at 1 µg/mL was able to sensitize both SH1000 and JE2 biofilms to killing by a combination of rifampicin and vancomycin, although the sensitization effect was significantly greater for strain SH1000 (6-7 log units) than for strain USA300 JE2 (1-2 log units). Similarly, Izano et al. [67] found that dispersin B efficiently detached pre-formed biofilms produced by MSSA strain SH1000 in 96-well microtiter plates, but not those produced by MRSA strain 252. However, dispersin B did not inhibit biofilm formation by either strain, and did not sensitize MSSA strain SH1000 biofilms to killing by cetylpyridinium chloride. Asai et al. [68] found that only one of 12 *S. aureus* strains isolated from patients with catheter-related bloodstream infections was susceptible to detachment by dispersin B when cultured in 96-well microtiter plates. Instead, most strains were sensitive to detachment by proteinase K. Similarly, Sugimoto et al. [69] found that dispersin B exhibited very limited biofilm

inhibition and detachment activities against a panel of 17 *S. aureus* strains (10 MSSA, 7 MRSA) isolated from hospital patients when tested in 96-well microtiter plates. In contrast, Rohde et al. [70] found that 18 out of 18 *S. aureus* strains isolated from prosthetic joint infections were efficiently detached 96-well plates by dispersin B. These differences may reflect differences in the media, culture conditions, bacterial strains, or methods used.

Several studies have shown that dispersin B sensitizes *S. aureus* biofilm to killing by a variety of antimicrobial agents including triclosan [71], cefamandole nafate [64], silver [72], antimicrobial peptide KSL-W [73], and a combination of rifampicin and clindamycin [74]. In general, dispersin B appears to sensitize both MSSA and MRSA biofilms to antibiotic killing.

16. Antibiofilm Activities of Dispersin B against *Staphylococcus epidermidis*

S. epidermidis is of interest because of its ability to cause biofilm-related implant- infections and its high susceptibility to biofilm inhibition and detachment by dispersin B [75,76]. Unlike *S. aureus*, only some *S. epidermidis* strains carry the *icaADBC* operon. It is still unclear whether the presence of *icaADBC* in *S. epidermidis* correlates with an increased risk of device infection. Numerous studies have shown that even low concentrations of dispersin B efficiently inhibit and detach PNAG-dependent *S. epidermidis* biofilms in vitro [68,70,71,77–85] and sensitize *S. epidermidis* biofilms to killing by antimicrobial agents including cetylpyridinium chloride [54,67], silver [72], and rifampicin [86].

17. Antibiofilm Activities of Dispersin B against Plant Pathogens

Dispersin B exhibits antibiofilm activity against several PNAG-producing plant pathogens including members of the genera *Ralstonia*, *Xanthomonas*, and *Pectobacterium*, as well as the plant biocontrol bacterium *Pseudomonas fluorescens* (Figure 6). *X. citri* subsp. *citri*, the causative agent of citrus canker, forms aggregates when cultured in broth (Figure 6A). These aggregates are readily dissolved by dispersin B, suggesting that PNAG mediates intercellular adhesion in this species. Dispersin B also inhibited biofilm formation by *R. solanacearum* in polystyrene microtiter plates (Figure 6B). *R. solanacearum* is a causative agent of bacterial wilt in wide range of host plants. Dispersin B also inhibited biofilm formation by *Pseudomonas fluorescens* [87] and binding of *P. fluorescens* planktonic cells to tomato roots (Figure 6C). Dispersin B also blocked biofilm formation by *P. carotovorum* in 96-well plates in vitro [88] as well as *P. carotovorum* infection of tobacco leaves in planta when *dspB* was expressed as a transgene (Figure 6D). Taken together, these findings suggest that plant-associated bacteria produce PNAG, and that PNAG contributes to intercellular adhesion, biofilm formation, plant colonization, and phytopathogenicity in vivo.




Figure 6. Effects of dispersin B on plant-associated bacteria. (A) *Xanthomonas citrisubsp. citri* strain 306 forms aggregates when cultured in broth (left panel). These aggregates were rapidly dissolved upon dispersin B treatment (right panel). (B) Biofilm formation by *Ralstonia solanacearum* strain Molk2 in polystyrene microtiter plates in the absence or presence of 20 $\mu\text{g/mL}$ dispersin B. Biofilms were stained with crystal violet. (C) Binding of *Pseudomonas fluorescens* strain WCS365 to tomato roots in the absence or presence of 20 $\mu\text{g/mL}$ dispersin B. Bacteria were mixed with 6-d-old tomato roots for 90 min. Roots were then crushed, mixed by vortex agitation, diluted, and plated on agar for CFU enumeration. Each data point represents one individual root. (D) Tobacco leaves infected with *Pectobacterium carotovorum* subsp. *carotovorum* strain ATCC 15713. Leaves were photographed 24 h after inoculation. Left, wild-type tobacco leaf; right, leaf from a transgenic tobacco plant expressing dispersin B. Source: Panels AC, J.B. Kaplan, unpublished data; Panel D, Ragunath et al. [88], N. Ramasubbu, unpublished data.

18. Enzyme Cocktails

Wen et al. [89] tested different combinations of dispersin B, proteinase K, and DNase I against biofilms produced by 10 multidrug resistant *Corynebacterium striatum* strains in 96-well microtiter plates. They found that the combination of 20 $\mu\text{g/mL}$ dispersin B and 20 $\mu\text{g/mL}$ proteinase K was most effective, dispersing at least 50% of the biofilm in 9/10 strains. Poilvache et al. [90] measured the ability of a tri-enzyme cocktail to detach biofilms produced by *S. aureus*, *S. epidermidis*, and *E. coli* on titanium surfaces. The enzymes were a nonspecific endonuclease from *Serratia marcescens*, an endoglucanase from *Aspergillus niger*, and dispersin B from *A. pleuropneumoniae*. The tri-enzyme combination exhibited greater biofilm detaching activity than any of the individual enzymes against *S. epidermidis*, but the combination was not more effective than endonuclease alone against *S. aureus* or dispersin B alone against *E. coli*. Exposure of tri-enzyme-treated biofilms with antibiotics resulted in a 2-3 log unit reduction of the total CFUs compared to that of biofilms treated with antibiotics alone in all three species. In a similar study from the same laboratory, Ruiz-Sorribas et al. [65] measured the ability of the tri-enzyme cocktail to detach three-species biofilms formed by *S. aureus*, *E. coli*, and *Candida albicans* in 96-well microtiter plates and on glass coverslips. They found that the addition of *Bacillus subtilis* lyticase or *B. licheniformis* subtilisin A was necessary to achieve significant

detachment of *C. albicans* biofilms. Pre-exposure of three-species biofilms to enzymes potentiated the activity of antimicrobial against the biofilms including the activity of caspofungin against *C. albicans*. Waryah et al. [91] showed that despite the inferiority of dispersin B to DNase I in dispersing *S. aureus* biofilms in a 96-well microtiter plate assay, both enzymes were equally efficient in enhancing the antibacterial efficiency of tobramycin. However, a combination of these two enzymes was found to be significantly less effective in enhancing the antimicrobial efficacy of tobramycin than the individual enzymes alone. Finally, Chiba et al. [92] investigated the effects of combined RNase A and dispersin B treatment on *S. aureus* biofilm formation grown in 96-well plates. When administered at low concentrations, neither enzyme alone dispersed mature biofilms. However, efficient dispersal was achieved by incubation with both enzymes, even at low concentrations. Taken together, these findings suggest that combining dispersin B with other biofilm matrix-degrading enzymes could increase their efficacy and spectrum of activity.

19. Dispersin B as a Medical Device Coating

Implanted medical devices and wound dressings coated with dispersin B have the potential to reduce the incidence of device infections and promote wound healing. Strategies for grafting dispersin B onto solid surfaces rely on either non-covalent absorption/adsorption of the enzyme to the surface, or its covalent attachment to the surface. These strategies are designed to achieve a high local concentration of dispersin B in the vicinity of the biomaterial surface.

One example of non-covalent binding of dispersin B to biomaterials was reported by Hagan et al. [93], who adsorbed dispersin B and amikacin into a commercially available, degradable hydrogel (VetriGel). Although these agents were successfully trapped within the hydrogel, the chemistry of the hydrogel did not support long-term retention of dispersin B, and trapped molecules underwent rapid elution within the first 24 h. A similar approach was reported by Kaplan et al. [75], who adsorbed dispersin B onto unmodified polyurethane and Teflon catheters and showed that the coated catheters efficiently resisted biofilm formation by *S. epidermidis*. The amount of enzyme retained on the surface was not measured, although catheters that were pre-coated and dried retained their antibiofilm activity after one month of storage.

Additional studies quantified adsorption of dispersin B on polyurethane disks, including those functionalized with acidic and basic groups [64]. These studies showed that coating polyurethane surfaces with dispersin B resulted in a >1 log unit reduction in *S. aureus* and *S. epidermidis* biofilm compared to the amount of biofilm formed on uncoated polyurethane. In addition, staphylococci grown on dispersin B-loaded polyurethane exhibited increased sensitivity to killing by cefamandole nafate compared to bacteria grown on uncoated polyurethane. In a similar study, Darouiche et al. [71] showed that polyurethane central venous catheters coated with dispersin B and triclosan efficiently resisted colonization by *S. aureus*, *S. epidermidis*, *E. coli*, and *C. albicans*.

In other studies, dispersin B was trapped within a porous structure of biodegradable asymmetric membranes that were designed for wound dressing applications [94,95]. The efficiency of dispersin B-loaded poly(3-hydroxybutyrate-co-4-hydroxybutyrate) membranes against *S. epidermidis* was modest (12% reduction) and occurred only in the case of pre-formed biofilms [94]. However, an improved membrane micro-nanostructure controlled by a polymeric porogen, as well as treatment of membrane surfaces with NaOH to create surface charge, enhanced the antibiofilm activity of the membrane. Specifically, *S. epidermidis* biofilm formation was inhibited by 33%, while 26% of pre-formed biofilm was destroyed [95]. By further improving the nanoporosity and efficiency of a poly(butylene-succinate-co-adipate)-based asymmetric membrane using a polymeric porogen, Bou Haidar et al. [63] showed that up to 80% of pre-formed *S. epidermidis* biofilms could be eradicated using this approach.

While a general feature of non-covalently adsorbed proteins is their tendency to desorb upon extensive dilution with a medium, controlling the nature and density of the adsorption sites can achieve strong binding of enzyme at surfaces. The latter scenario was realized by employing the layer-by-layer technique to construct surface hydrogels with a high density of basic groups, followed by trapping of dispersin B within the coatings [96]. Although dispersin B was retained within the

coating only by electrostatic interactions, the coatings did not elute dispersin B in solution, were highly stable over a wide range of pH values, and maintained their antibiofilm function after a several-day-long preincubation in buffer solutions. These dispersin B-loaded coatings inhibited biofilm formation by a clinical strain of *S. epidermidis* (Figure 7A). Importantly, this approach enables facile control of the amount of immobilized dispersin B by modulating the number of polymer layers in the surface hydrogels.




Figure 7. Abiotic surfaces coated with dispersin B resist *S. epidermidis* biofilm formation and surface attachment. (A) Biofilm formation by *S. epidermidis* strain NJ9709 on glass slides containing an ultrathin layered poly(allylamine hydrochloride) (PAH) hydrogel coating (left panel), or a PAH coating loaded with dispersin B (right panel). Bacteria were cultured inside plastic cloning cylinders (5-mm-inside-diam) that were attached to the slide with high vacuum grease. After 12 h, the biofilms were rinsed, the cloning cylinders were removed, and the slides were photographed. The rings correspond to the footprints of the cloning cylinders. The biofilm appeared as a white film on the unloaded PAH layer which was absent on the dispersin B-loaded PAH layer. (B) Attachment of *S. epidermidis* strain ATCC35984 to uncoated stainless steel disks, or to disks coated with polydopamine- or plasma-based coatings with or without grafted dispersin B. Source: Panel A, [96]; panel B, redrawn from [98].

An alternative strategy for localized protection against biofilm growth is surface functionalization via covalent attachment of enzymes. For applications in regenerative medicine, biodegradable polyhydroxyalkanoate (PHA)-based fiber meshes were functionalized with dispersin B along with a synthetic antibacterial peptide by covalent conjugation, which was achieved by using reactive star-shape macromolecules as an additive to a PHA solution [84]. Efficient prevention of bacterial adhesion (88%) and complete inhibition of *S. epidermidis* biofilm formation confirmed successful presentation of the antibiofilm and antimicrobial agents at the fiber surface.

Covalent modification of solid surfaces, such as stainless steel mimicking the surfaces of biomedical implants, enables a convenient and rapid method for creating reactive surface groups using atmospheric plasma technology for rapid modification of surfaces with protein-binding interlayers [97,98]. In one example, epoxy-rich films were created by introducing glycidyl methacrylate in the plasma followed by covalent immobilization of dispersin B and a sulfomethoxazole-degrading enzyme (laccase). These coatings resulted in a 79-84% reduction in adherent *S. epidermidis* bacteria [97]. The atmospheric plasma technique was also used to deposit acrylic-based interlayers containing chemically reactive catechol/quinone groups on metallic surfaces for subsequent immobilization of dispersin B [98]. This biomimetic approach with both solution-adsorbed polydopamine (PDA) and plasma-based interlayers showed high antibiofilm activity against *S. epidermidis* (Figure 7B).

Faure et al. [99] used the redox and adhesive properties of 3,4-dihydroxy-L-phenylalanine (DOPA) to apply surface modifications on stainless steel surfaces for enzyme immobilization. While a cationic polyelectrolyte-bearing catechol unit that mimics the composition of adhesive proteins present in mussel foot was used to coat the surface, the capability of a poly(methacrylamide) bearing quinone groups for crosslinking with amine groups was used to prepare nanogels that can be easily deposited to stainless steel from aqueous solution. Dispersin B containing thiol groups was then covalently anchored on the nanogels, resulting in coatings which provided long-term activity against *S. epidermidis* [99].

A different, potentially substrate-agnostic approach was recently developed that involves covalent conjugation of dispersin B to spider silk protein using the transpeptidase sortase A [100,101]. This approach is based on the ability of silk protein to self-assemble via non-covalent interactions within a coating. The ability to use pre-assembly or post-assembly enzyme conjugation routes provides flexibility in optimizing surface presentation of enzymes because of the ease and the efficiency of the conjugation procedure [100].

Despite specific advantages and disadvantages of the above approaches, they all have the potential to create bioactive materials that allow local treatment of complex infections without the need for invasive procedures, and all deserve further development.

20. Enzymatic Bacteriophages

Bacteriophages are being investigated as an alternative to antibiotics for the treatment of bacterial infections including those caused by biofilms. Lu & Collins [102] engineered the lytic *E. coli*-specific phage T7 to express dispersin B intracellularly during infection so dispersin B would be released into the extracellular environment upon cell lysis. When tested against pre-formed biofilms formed by *E. coli* strain TG1 on 96-peg lids, the engineered enzymatic phage reduced bacterial biofilm cell counts by ≈ 4.5 log units ($\approx 99.997\%$ removal), which was two log units greater than the reduction achieved with non-enzymatic phages. Schmerer et al. [103] confirmed that dispersin B-expressing T7 phages were superior to non-enzymatic phages for eradicating *E. coli* biofilms grown for 12-16 h in 24-well microtiter plates, but they were only marginally better than non-enzymatic phages against *E. coli* biofilms grown for 7 d in silicone tubing. These studies demonstrate the feasibility of using engineered enzymatic bacteriophage as an antibiofilm strategy.

21. In Vivo Studies

Several studies demonstrated that dispersin B exhibits antibiofilm activity of against staphylococci in vivo. Kaplan et al. [104] showed that dispersin B decreased the ability of *S. epidermidis* to colonize pig skin by 66-78% compared to a no enzyme control.

Gawande et al. [72] found that dispersin B combined with a silver wound dressing showed an 80% reduction in *S. aureus* MRSA bioburden in a chronic wound mouse model, compared to a 14% reduction when wounds were treated with a silver wound dressing alone. Darouiche et al. [71] tested dispersin B in against *S. aureus* in a rabbit catheter infection model. A total of 1 out of 30 catheters coated with dispersin B plus triclosan were colonized with *S. aureus*, compared to 29/30 uncoated control catheters. Finally, Serrera et al. [105] showed that dispersin B, when used in combination with

teicoplanin as a catheter lock solution in a sheep model of port-related bloodstream infection, reduced the number of *S. aureus* infections from 100% to 50% (8/8 versus 4/8), and the number of deaths from 50% to 0% (4/8 versus 0/8), compared to a teicoplanin catheter lock solution alone.

21. Commercial Development

Dispersin B was licensed to the Canadian company, Kane Biotech Inc., in 2004, initially for the development of medical device coatings and cosmetics. Pharmaceutical grade dispersin B (also known as DispersinB®) has been purified from a recombinant strain of *E. coli*, and the enzyme has undergone extensive biocompatibility testing. Recombinant dispersin B exhibited no cytotoxicity against L-929 cells in vitro, and no mutagenicity or genotoxicity in the Ames test, in an in vitro human peripheral blood lymphocytes micronuclei assay, and in an in vivo rat blood reticulocyte assay that monitors chromosomal damage. Additional in vitro and in vivo biocompatibility testing showed that dispersin B was non-pyrogenic, non-sensitizing, and non-irritating; exhibited no acute or sub-chronic systemic toxicity; and was not detectable in blood when applied to full-thickness dermal wounds in pigs. These results suggest that dispersin B is biocompatible and safe for use on human skin. DispersinB is also compatible with many antimicrobials, salts, preservatives, and excipients such as polyols, enabling it to be formulated into a plurality of products. For commercialization, dispersin B has been formulated into a gel containing poloxamer 407, glycerol, preservatives, and buffered phosphate. This formulation exhibits thermosensitive viscosity properties which enable it to form a gel on the skin. This dispersin B gel formulation has undergone stability and biocompatibility testing in accordance with ISO 10993 standards for prolonged exposure to breached/compromised skin with positive results. Kane Biotech has also obtained promising results with dispersin B gel in a pig wound healing study. The product has been designated as a biologic/device combination product with the primary mode of action being the device. Dispersin B gel is currently undergoing the Investigational Device Exemption (IDE) review process with the FDA Center for Devices and Radiological Health (CDRH), with a plan to commence clinical trials for chronic wounds and acne vulgaris in 2025.

22. Conclusions

Dispersin B is a well characterized PNAG-degrading enzyme that is both a useful tool for biofilm research and a potential therapeutic agent for the treatment and prevention of biofilm-related infections in plants and animals. Anti-PNAG antibodies have been shown to protect mice against local and/or systemic infections by various microbial pathogens including *Streptococcus pyogenes*, *S. pneumoniae*, *Listeria monocytogenes*, *Neisseria meningitidis* serogroup B, *C. albicans*, and *Plasmodium berghei* ANKA, and against colonic pathology in a model of infectious colitis [42]. These findings validate PNAG as an antimicrobial target. Because of the large number of bacteria, fungi, and protozoa that produce PNAG [42,43], dispersin B may have broad applicability as an antibiofilm agent. The most practical applications will be those where dispersin B can be used as a topical agent in the form of a gel, ointment, or spray in combination with an antimicrobial. These may include agents for the treatment of wounds such as surgical site wounds, traumatic wounds, burns, and chronic wounds including diabetic foot ulcers; for the treatment and prevention of dermatoses such as atopic dermatitis and acne vulgaris; for the treatment of ocular infections such as blepharitis and corneal ulcers; for the treatment of aural infections such as otitis media; and as a pre-surgical skin antiseptic. Other potential applications include catheter lock solutions and irrigation solutions or coatings for implanted medical devices.

Acknowledgements: Molecular graphics and analyses performed with UCSF ChimeraX, developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco, with support from National Institutes of Health grant R01-GM129325 and the Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases.

Author Contributions: J.B.K., S.A.S., M.S., and N.S. wrote the original draft of the manuscript. All authors reviewed and edited the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This preparation and publication of this article was funded in part by the Health Corporation of the Galilee Medical Center (Nahariya, Israel) and Kane Biotech, Inc. (Winnipeg, Canada).

Data Availability Statement: No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Conflicts of Interest: J.B.K. serves as an advisor for, owns equity in, and receives royalties. from Kane Biotech Inc., Winnipeg, Canada. This company is developing antibiofilm applications related to dispersin B. M.S. is an employee of Kane Biotech Inc., manufacturer of dispersin B (DispersinB®), and own company stocks and stock options.

References

1. Penesyan, A.; Paulsen, I. T.; Kjelleberg, S.; Gillings, M. R. Three faces of biofilms: a microbial lifestyle, a nascent multicellular organism, and an incubator for diversity. *NPJ Biofilms Microbiomes* 2021, 7, 80. DOI: 10.1038/s41522-021-00251-2
2. Penesyan, A.; Gillings, M.; Paulsen, I. T. Antibiotic discovery: combatting bacterial resistance in cells and in biofilm communities. *Molecules* 2015, 20, 5286-5298. DOI: 10.3390/molecules20045286
3. Abdelhamid, A. G.; Yousef, A. E. Combating bacterial biofilms: current and emerging antibiofilm strategies for treating persistent infections. *Antibiotics (Basel)* 2023, 12. DOI: 10.3390/antibiotics12061005
4. Jiang, Y.; Geng, M.; Bai, L. Targeting biofilms therapy: current research strategies and development hurdles. *Microorganisms* 2020, 8, 1222. DOI: 10.3390/microorganisms8081222
5. Kaplan, J. B. Therapeutic potential of biofilm-dispersing enzymes. *Int. J. Artif. Organs* 2009, 32, 545-554. DOI: 10.1177/039139880903200903
6. Ramakrishnan, R.; Singh, A. K.; Singh, S.; Chakravorty, D.; Das, D. Enzymatic dispersion of biofilms: an emerging biocatalytic avenue to combat biofilm-mediated microbial infections. *J. Biol. Chem.* 2022, 298, 102352. DOI: 10.1016/j.jbc.2022.102352
7. Wang, S.; Zhao, Y.; Breslawec, A. P.; Liang, T.; Deng, Z.; Kuperman, L. L.; Yu, Q. Strategy to combat biofilms: a focus on biofilm dispersal enzymes. *NPJ Biofilms Microbiomes* 2023, 9, 63. DOI: 10.1038/s41522-023-00427-y
8. Nguyen, H. T. T.; Nguyen, T. H.; Otto, M. The staphylococcal exopolysaccharide PIA - biosynthesis and role in biofilm formation, colonization, and infection. *Comput. Struct. Biotechnol. J.* 2020, 18, 3324-3334. DOI: 10.1016/j.csbj.2020.10.027
9. Fine, D. H.; Furgang, D.; Kaplan, J.; Charlesworth, J.; Figurski, D. H. Tenacious adhesion of *Actinobacillus actinomycetemcomitans* strain CU1000 to salivary-coated hydroxyapatite. *Arch. Oral Biol.* 1999, 44, 1063-1076. DOI: 10.1016/s0003-9969(99)00089-8
10. Kaplan, J. B.; Meyenhofer, M. F.; Fine, D. H. Biofilm growth and detachment of *Actinobacillus actinomycetemcomitans*. *J. Bacteriol.* 2003, 185, 1399-1404. DOI: 10.1128/JB.185.4.1399-1404.2003
11. Kaplan, J. B.; Ragunath, C.; Ramasubbu, N.; Fine, D. H. Detachment of *Actinobacillus actinomycetemcomitans* biofilm cells by an endogenous beta-hexosaminidase activity. *J. Bacteriol.* 2003, 185, 4693-4698. DOI: 10.1128/JB.185.16.4693-4698.2003
12. Stacy, A.; Everett, J.; Jorth, P.; Trivedi, U.; Rumbaugh, K. P.; Whiteley, M. Bacterial fight-and-flight responses enhance virulence in a polymicrobial infection. *Proc. Natl. Acad. Sci. U S A* 2014, 111, 7819-7824. DOI: 10.1073/pnas.1400586111
13. Zhang, Q.; Peng, L.; Han, W.; Chen, H.; Tang, H.; Chen, X.; Langford, P. R.; Huang, Q.; Zhou, R.; Li, L. The morphology and metabolic changes of *Actinobacillus pleuropneumoniae* during its growth as a biofilm. *Vet. Res.* 2023, 54, 42. DOI: 10.1186/s13567-023-01173-x
14. Kaplan, J. B.; Velliyagounder, K.; Ragunath, C.; Rohde, H.; Mack, D.; Knobloch, J. K.; Ramasubbu, N. Genes involved in the synthesis and degradation of matrix polysaccharide in *Actinobacillus actinomycetemcomitans* and *Actinobacillus pleuropneumoniae* biofilms. *J. Bacteriol.* 2004, 186, 8213-8220. DOI: 10.1128/JB.186.24.8213-8220.2004
15. Michael, G. B.; Bossé, J. T.; Schwartz, S. Antimicrobial resistance in Pasteurellaceae of veterinary origin. *Microbiol. Spectrum* 2017, 6, ARBA-0022-2017. DOI: 10.1128/microbiolspec.ARBA-0022-2017
16. Ono, R.; Kitagawa, I.; Kobayashi, Y. *Cardiobacterium hominis* infective endocarditis: a literature review. *Am. Heart J. Plus* 2023, 26, 100248. DOI: 10.1016/j.ahjo.2022.100248
17. Stacy, A.; Abraham, N.; Jorth, P.; Whiteley, M. Microbial community composition impacts pathogen iron availability during polymicrobial infection. *PLoS Pathog.* 2016, 12, e1006084. DOI: 10.1371/journal.ppat.1006084

18. Ishikawa, K. H.; Bueno, M. R.; Kawamoto, D.; Simionato, M. R. L.; Mayer, M. P. A. Lactobacilli postbiotics reduce biofilm formation and alter transcription of virulence genes of *Aggregatibacter actinomycetemcomitans*. *Mol. Oral. Microbiol.* 2021, 36, 92-102. DOI: 10.1111/omi.12330
19. Shakya, S.; Danshiitsoodol, N.; Noda, M.; Inoue, Y.; Sugiyama, M. 3-Phenyllactic acid generated in medicinal plant extracts fermented with plant-derived lactic acid bacteria inhibits the biofilm synthesis of *Aggregatibacter actinomycetemcomitans*. *Front. Microbiol.* 2022, 13, 991144. DOI: 10.3389/fmicb.2022.991144
20. Ramasubbu, N.; Thomas, L. M.; Ragunath, C.; Kaplan, J. B. Structural analysis of dispersin B, a biofilm-releasing glycoside hydrolase from the periodontopathogen *Actinobacillus actinomycetemcomitans*. *J. Mol. Biol.* 2005, 349, 475-486. DOI: 10.1016/j.jmb.2005.03.082
21. Yakandawala, N.; Gawande, P. V.; LoVetri, K.; Romeo, T.; Kaplan, J. B.; Madhyastha, S. Enhanced expression of engineered ACA-less beta-1, 6-N-acetylglucosaminidase (dispersin B) in *Escherichia coli*. *J. Ind. Microbiol. Biotechnol.* 2009, 36, 1297-1305. DOI: 10.1007/s10295-009-0613-0
22. Gökçen, A.; Vilcinskis, A.; Wiesner, J. Methods to identify enzymes that degrade the main extracellular polysaccharide component of *Staphylococcus epidermidis* biofilms. *Virulence* 2013, 4, 260-270. DOI: 10.4161/viru.23560
23. Zeng, K.; Sun, E. J.; Liu, Z. W.; Guo, J.; Yuan, C.; Yang, Y.; Xie, H. Synthesis of magnetic nanoparticles with an IDA or TED modified surface for purification and immobilization of poly-histidine tagged proteins. *RSC Adv.* 2020, 10, 11524-11534. DOI: 10.1039/c9ra10473a
24. Opdensteinen, P. Assessment of a novel high-throughput process development platform for biopharmaceutical protein production. Aachen University, Ph.D. thesis 2023.
25. Prag, G.; Papanikolaou, Y.; Tavlas, G.; Vorgias, C. E.; Petratos, K.; Oppenheim, A. B. Structures of chitinase mutants complexed with the substrate di-N-acetyl-D-glucosamine: the catalytic role of the conserved acidic pair, aspartate 539 and glutamate 540. *J. Mol. Biol.* 2000, 300, 611-617. DOI: 10.1006/jmbi.2000.3906
26. Manuel, S. G.; Ragunath, C.; Sait, H. B.; Izano, E. A.; Kaplan, J. B.; Ramasubbu, N. Role of active-site residues of dispersin B, a biofilm-releasing beta-hexosaminidase from a periodontal pathogen, in substrate hydrolysis. *FEBS J.* 2007, 274, 5987-5999. DOI: 10.1111/j.1742-4658.2007.06121.x
27. Williams, S. J.; Mark, B. L.; Vocadlo, D. J.; James, M. N.; Withers, S. G. Aspartate 313 in the *Streptomyces plicatus* hexosaminidase plays a critical role in substrate-assisted catalysis by orienting the 2-acetamido group and stabilizing the transition state. *J. Biol. Chem.* 2002, 277, 40055-40065. DOI: 10.1074/jbc.M206481200
28. Chibba, A.; Dasgupta, S.; Yakandawala, N.; Madhyastha, S.; Nitz, M. Chromogenic carbamate and acetal substrates for glycosaminidases. *J. Carbohydr. Chem.* 2011, 30, 549-558. DOI: 10.1080/07328303.2011.610543
29. Fazekas, E.; Kandra, L.; Gyemant, G. Model for beta-1,6-N-acetylglucosamine oligomer hydrolysis catalysed by DispersinB, a biofilm degrading enzyme. *Carbohydr. Res.* 2012, 363, 7-13. DOI: 10.1016/j.carres.2012.09.016
30. Fekete, A.; Borbas, A.; Gyemant, G.; Kandra, L.; Fazekas, E.; Ramasubbu, N.; Antus, S. Synthesis of beta-(1->6)-linked N-acetyl-D-glucosamine oligosaccharide substrates and their hydrolysis by Dispersin B. *Carbohydr. Res.* 2011, 346, 1445-1453. DOI: 10.1016/j.carres.2011.03.029
31. Kerrigan, J. E.; Ragunath, C.; Kandra, L.; Gyemant, G.; Liptak, A.; Janossy, L.; Kaplan, J. B.; Ramasubbu, N. Modeling and biochemical analysis of the activity of antibiofilm agent Dispersin B. *Acta Biol. Hung.* 2008, 59, 439-451. DOI: 10.1556/ABiol.59.2008.4.5
32. Wang, S.; Breslawec, A. P.; Poulin, M. B. Multifunctional fluorescent probes for high-throughput characterization of hexosaminidase enzyme activity. *Bioorg. Chem.* 2022, 119, 105532. DOI: 10.1016/j.bioorg.2021.105532
33. Wang, S.; Breslawec, A. P.; Alvarez, E.; Tyrlik, M.; Li, C.; Poulin, M. B. Differential recognition of deacetylated PNAG oligosaccharides by a biofilm degrading glycosidase. *ACS Chem. Biol.* 2019, 14, 1998-2005. DOI: 10.1021/acscchembio.9b00467
34. Breslawec, A. P.; Wang, S.; Monahan, K. N.; Barry, L. L.; Poulin, M. B. The endoglycosidase activity of Dispersin B is mediated through electrostatic interactions with cationic poly-beta-(1->6)-N-acetylglucosamine. *FEBS J.* 2023, 290, 1049-1059. DOI: 10.1111/febs.16624
35. Breslawec, A. P.; Wang, S.; Li, C.; Poulin, M. B. Anionic amino acids support hydrolysis of poly-beta-(1,6)-N-acetylglucosamine exopolysaccharides by the biofilm dispersing glycosidase Dispersin B. *J. Biol. Chem.* 2021, 296, 100203. DOI: 10.1074/jbc.RA120.015524
36. Abdelkader, J.; Alelyani, M.; Alashban, Y.; Alghamdi, S. A.; Bakkour, Y. Modification of dispersin B with cyclodextrin-ciprofloxacin derivatives for treating staphylococcal. *Molecules* 2023, 28. DOI: 10.3390/molecules28145311
37. Liu, Z.; Zhao, Z.; Zeng, K.; Xia, Y.; Xu, W.; Wang, R.; Guo, J.; Xie, H. Functional immobilization of a biofilm-releasing glycoside hydrolase dispersin B on magnetic nanoparticles. *Appl. Biochem. Biotechnol.* 2022, 194, 737-747. DOI: 10.1007/s12010-021-03673-y

38. Chen, K. J.; Lee, C. K. Twofold enhanced dispersin B activity by N-terminal fusion to silver-binding peptide for biofilm eradication. *Int. J. Biol. Macromol.* 2018, 118, 419-426. DOI: 10.1016/j.ijbiomac.2018.06.066
39. Garrido, V.; Pinero-Lambea, C.; Rodriguez-Arce, I.; Paetzold, B.; Ferrar, T.; Weber, M.; Garcia-Ramallo, E.; Gallo, C.; Collantes, M.; Penuelas, I.; et al. Engineering a genome-reduced bacterium to eliminate *Staphylococcus aureus* biofilms in vivo. *Mol. Syst. Biol.* 2021, 17, e10145. DOI: 10.15252/msb.202010145
40. Ghalsasi V. V.; Sourjik, V. Engineering *Escherichia coli* to disrupt poly-N-acetylglucosamine containing bacterial biofilms. *Curr. Synthetic Sys. Biol.* 2016, 4, 1. DOI: 10.4172/2332-0737.1000130
41. Ragunath, C.; DiFranco, K.; Shanmugam, M.; Gopal, P.; Vyas, V.; Fine, D. H.; Cugini, C.; Ramasubbu, N. Surface display of *Aggregatibacter actinomycetemcomitans* autotransporter Aae and dispersin B hybrid act as antibiofilm agents. *Mol. Oral Microbiol.* 2016, 31, 329-339. DOI: 10.1111/omi.12126
42. Cywes-Bentley, C.; Skurnik, D.; Zaidi, T.; Roux, D.; Deoliveira, R. B.; Garrett, W. S.; Lu, X.; O'Malley, J.; Kinzel, K.; Zaidi, T.; et al. Antibody to a conserved antigenic target is protective against diverse prokaryotic and eukaryotic pathogens. *Proc. Natl. Acad. Sci. U S A* 2013, 110, E2209-2218. DOI: 10.1073/pnas.1303573110
43. Gening, M. L.; Pier, G. B.; Nifantiev, N. E. Broadly protective semi-synthetic glycoconjugate vaccine against pathogens capable of producing poly-(1→6)-N-acetyl-D-glucosamine exopolysaccharide. *Drug Discov. Today Technol.* 2020, 35-36, 13-21. DOI: 10.1016/j.ddtec.2020.09.002
44. Yoong, P.; Cywes-Bentley, C.; Pier, G. B. Poly-N-acetylglucosamine expression by wild-type *Yersinia pestis* is maximal at mammalian, not flea, temperatures. *mBio* 2012, 3, e00217-00212. DOI: 10.1128/mBio.00217-12
45. Roux, D.; Cywes-Bentley, C.; Zhang, Y. F.; Pons, S.; Konkol, M.; Kearns, D. B.; Little, D. J.; Howell, P. L.; Skurnik, D.; Pier, G. B. Identification of poly-N-acetylglucosamine as a major polysaccharide component of the *Bacillus subtilis* biofilm matrix. *J. Biol. Chem.* 2015, 290, 19261-19272. DOI: 10.1074/jbc.M115.648709
46. Spiliopoulou, A. I.; Krevvata, M. I.; Kolonitsiou, F.; Harris, L. G.; Wilkinson, T. S.; Davies, A. P.; Dimitracopoulos, G. O.; Karamanos, N. K.; Mack, D.; Anastassiou, E. D. An extracellular *Staphylococcus epidermidis* polysaccharide: relation to polysaccharide intercellular adhesin and its implication in phagocytosis. *BMC Microbiol.* 2012, 12, 76. DOI: 10.1186/1471-2180-12-76
47. Yakandawala, N.; Gawande, P. V.; LoVetri, K.; Cardona, S. T.; Romeo, T.; Nitz, M.; Madhyastha, S. Characterization of the poly-beta-1,6-N-acetylglucosamine polysaccharide component of *Burkholderia* biofilms. *Appl. Environ. Microbiol.* 2011, 77, 8303-8309. DOI: 10.1128/AEM.05814-11
48. Sugimoto, S.; Iwamoto, T.; Takada, K.; Okuda, K.; Tajima, A.; Iwase, T.; Mizunoe, Y. *Staphylococcus epidermidis* Esp degrades specific proteins associated with *Staphylococcus aureus* biofilm formation and host-pathogen interaction. *J. Bacteriol.* 2013, 195, 1645-1655. DOI: 10.1128/JB.01672-12
49. Chiba, A.; Sugimoto, S.; Sato, F.; Hori, S.; Mizunoe, Y. A refined technique for extraction of extracellular matrices from bacterial biofilms and its applicability. *Microb. Biotechnol.* 2015, 8, 392-403. DOI: 10.1111/1751-7915.12155
50. Eddenden, A.; Kitova, E. N.; Klassen, J. S.; Nitz, M. An inactive dispersin B probe for monitoring PNAG production in biofilm formation. *ACS Chem. Biol.* 2020, 15, 1204-1211. DOI: 10.1021/acscchembio.9b00907
51. Eddenden, A.; Nitz, M. Applications of an inactive dispersin B probe to monitor biofilm polysaccharide production. *Methods Enzymol.* 2022, 665, 209-231. DOI: 10.1016/bs.mie.2021.11.006
52. Al Laham, N.; Rohde, H.; Sander, G.; Fischer, A.; Hussain, M.; Heilmann, C.; Mack, D.; Proctor, R.; Peters, G.; Becker, K.; von Eiff, C. Augmented expression of polysaccharide intercellular adhesin in a defined *Staphylococcus epidermidis* mutant with the small-colony-variant phenotype. *J. Bacteriol.* 2007, 189, 4494-4501. DOI: 10.1128/JB.00160-07
53. Amini, S.; Goodarzi, H.; Tavazoie, S. Genetic dissection of an exogenously induced biofilm in laboratory and clinical isolates of *E. coli*. *PLoS Pathog.* 2009, 5, e1000432. DOI: 10.1371/journal.ppat.1000432
54. Ganeshnarayan, K.; Shah, S. M.; Libera, M. R.; Santostefano, A.; Kaplan, J. B. Poly-N-acetylglucosamine matrix polysaccharide impedes fluid convection and transport of the cationic surfactant cetylpyridinium chloride through bacterial biofilms. *Appl. Environ. Microbiol.* 2009, 75, 1308-1314. DOI: 10.1128/AEM.01900-08
55. Lin, M. H.; Shu, J. C.; Lin, L. P.; Chong, K. y.; Cheng, Y. W.; Du, J. F.; Liu, S.-T. Elucidating the crucial role of poly N-acetylglucosamine from *Staphylococcus aureus* in cellular adhesion and pathogenesis. *PLoS ONE* 2015, 10, e0124216. DOI: 10.1371/journal.pone.0124216
56. Mlynek, K. D.; Bullock, L. L.; Stone, C. J.; Curran, L. J.; Sadykov, M. R.; Bayles, K. W.; Brinsmade, S. R. Genetic and biochemical Analysis of CodY-mediated cell aggregation in *Staphylococcus aureus* reveals an interaction between extracellular DNA and polysaccharide in the extracellular matrix. *J. Bacteriol.* 2020, 202. DOI: 10.1128/JB.00593-19
57. Wu, J.; Xi, C. Evaluation of different methods for extracting extracellular DNA from the biofilm matrix. *Appl. Environ. Microbiol.* 2009, 75, 5390-5395. DOI: 10.1128/AEM.00400-09
58. Wu, J.; Xi, C. Enzymatic method for extracting extracellular DNA in biofilm matrix. *Cold Spring Harb. Protoc.* 2010, 7, pdb prot5456. DOI: 10.1101/pdb.prot5456

59. Kaplan, J. B.; Cywes-Bentley, C.; Pier, G. B.; Yakandawala, N.; Sailer, M.; Edwards, M. S.; Kridin, K. Poly-beta-(1-->6)-N-acetyl-D-glucosamine mediates surface attachment, biofilm formation, and biocide resistance in *Cutibacterium acnes*. *Front Microbiol.* 2024, 15, 1386017. DOI: 10.3389/fmicb.2024.1386017
60. Izano, E. A.; Wang, H.; Ragunath, C.; Ramasubbu, N.; Kaplan, J. B. Detachment and killing of *Aggregatibacter actinomycetemcomitans* biofilms by dispersin B and SDS. *J. Dent. Res.* 2007, 86, 618-622. DOI: 10.1177/154405910708600707
61. Atwood, D. N.; Loughran, A. J.; Courtney, A. P.; Anthony, A. C.; Meeker, D. G.; Spencer, H. J.; Gupta, R. K.; Lee, C. Y.; Beenken, K. E.; Smeltzer, M. S. Comparative impact of diverse regulatory loci on *Staphylococcus aureus* biofilm formation. *Microbiologyopen* 2015, 4, 436-451. DOI: 10.1002/mbo3.250
62. LeBel, G.; Haas, B.; Adam, A. -A.; Veilleux, M. -P.; Ben Lagha, A.; Grenier, D. Effect of cinnamon (*Cinnamomum verum*) bark essential oil on the halitosis-associated bacterium *Solobacterium moorei* and in vitro cytotoxicity. *Arch. Oral Biol.* 2017, 83, 97-104. DOI: 10.1016/j.archoralbio.2017.07.005
63. Bou Haidar, N.; Marais, S.; De, E.; Schaumann, A.; Barreau, M.; Feuilloley, M. G. J.; Duncan, A. C. Chronic wound healing: a specific antibiofilm protein-asymmetric release system. *Mater. Sci. Eng. C Mater. Biol. Appl.* 2020, 106, 110130. DOI: 10.1016/j.msec.2019.110130
64. Donelli, G.; Francolini, I.; Romoli, D.; Guaglianone, E.; Piozzi, A.; Ragunath, C.; Kaplan, J. B. Synergistic activity of dispersin B and cefamandole nafate in inhibition of staphylococcal biofilm growth on polyurethanes. *Antimicrob. Agents Chemother.* 2007, 51, 2733-2740. DOI: 10.1128/AAC.01249-06
65. Ruiz-Sorribas, A.; Poilvache, H.; Kamarudin, N. H. N.; Braem, A.; Van Bambeke, F. Hydrolytic enzymes as potentiators of antimicrobials against an inter-kingdom biofilm model. *Microbiol. Spectr.* 2022, 10, e0258921. DOI: 10.1128/spectrum.02589-21
66. Hogan, S.; Zapotoczna, M.; Stevens, N. T.; Humphreys, H.; O'Gara, J. P.; O'Neill, E. Potential use of targeted enzymatic agents in the treatment of *Staphylococcus aureus* biofilm-related infections. *J. Hosp. Infect.* 2017, 96, 177-182. DOI: 10.1016/j.jhin.2017.02.008
67. Izano, E. A.; Amarante, M. A.; Kher, W. B.; Kaplan, J. B. Differential roles of poly-N-acetylglucosamine surface polysaccharide and extracellular DNA in *Staphylococcus aureus* and *Staphylococcus epidermidis* biofilms. *Appl. Environ. Microbiol.* 2008, 74, 470-476. DOI: 10.1128/AEM.02073-07
68. Asai, K.; Yamada, K.; Yagi, T.; Baba, H.; Kawamura, I.; Ohta, M. Effect of incubation atmosphere on the production and composition of staphylococcal biofilms. *J. Infect. Chemother.* 2015, 21, 55-61. DOI: 10.1016/j.jiac.2014.10.001
69. Sugimoto, S.; Sato, F.; Miyakawa, R.; Chiba, A.; Onodera, S.; Hori, S.; Mizunoe, Y. Broad impact of extracellular DNA on biofilm formation by clinically isolated methicillin-resistant and -sensitive strains of *Staphylococcus aureus*. *Sci. Rep.* 2018, 8, 2254. DOI: 10.1038/s41598-018-20485-z
70. Rohde, H.; Burandt, E. C.; Siemssen, N.; Frommelt, L.; Burdelski, C.; Wurster, S.; Scherpe, S.; Davies, A. P.; Harris, L. G.; Horstkotte, M. A.; et al. Polysaccharide intercellular adhesin or protein factors in biofilm accumulation of *Staphylococcus epidermidis* and *Staphylococcus aureus* isolated from prosthetic hip and knee joint infections. *Biomaterials* 2007, 28, 1711-1720. DOI: 10.1016/j.biomaterials.2006.11.046
71. Darouiche, R. O.; Mansouri, M. D.; Gawande, P. V.; Madhyastha, S. Antimicrobial and antibiofilm efficacy of triclosan and DispersinB combination. *J. Antimicrob. Chemother.* 2009, 64, 88-93. DOI: 10.1093/jac/dkp158
72. Gawande, P. V.; Clinton, A. P.; LoVetri, K.; Yakandawala, N.; Rumbaugh, K. P.; Madhyastha, S. Antibiofilm efficacy of DispersinB(R) wound spray used in combination with a silver wound dressing. *Microbiol. Insights* 2014, 7, 9-13. DOI: 10.4137/MBI.S13914
73. Gawande, P. V.; Leung, K. P.; Madhyastha, S. Antibiofilm and antimicrobial efficacy of DispersinB(R)-KSL-W peptide-based wound gel against chronic wound infection associated bacteria. *Curr. Microbiol.* 2014, 68, 635-641. DOI: 10.1007/s00284-014-0519-6
74. Belfield, K.; Bayston, R.; Hajduk, N.; Levell, G.; Birchall, J. P.; Daniel, M. Evaluation of combinations of putative anti-biofilm agents and antibiotics to eradicate biofilms of *Staphylococcus aureus* and *Pseudomonas aeruginosa*. *J. Antimicrob. Chemother.* 2017, 72, 2531-2538. DOI: 10.1093/jac/dkx192
75. Kaplan, J. B.; Ragunath, C.; Velliyagounder, K.; Fine, D. H.; Ramasubbu, N. Enzymatic detachment of *Staphylococcus epidermidis* biofilms. *Antimicrob. Agents Chemother.* 2004, 48, 2633-2636. DOI: 10.1128/AAC.48.7.2633-2636.2004
76. Brindle, E. R.; Miller, D. A.; Stewart, P. S. Hydrodynamic deformation and removal of *Staphylococcus epidermidis* biofilms treated with urea, chlorhexidine, iron chloride, or DispersinB. *Biotechnol. Bioeng.* 2011, 108, 2968-2977. DOI: 10.1002/bit.23245
77. Burton, E.; Yakandawala, N.; LoVetri, K.; Madhyastha, M. S. A microplate spectrofluorometric assay for bacterial biofilms. *J. Ind. Microbiol. Biotechnol.* 2007, 34, 1-4. DOI: 10.1007/s10295-006-0086-3
78. Chaignon, P.; Sadvskaya, I.; Ragunah, C.; Ramasubbu, N.; Kaplan, J. B.; Jabbouri, S. Susceptibility of staphylococcal biofilms to enzymatic treatments depends on their chemical composition. *Appl. Microbiol. Biotechnol.* 2007, 75, 125-132. DOI: 10.1007/s00253-006-0790-y

79. Dobrynina, O. Y.; Bolshakova, T. N.; Umyarov, A. M.; Boksha, I. S.; Lavrova, N. V.; Grishin, Lyashchuk, A. M.; Galushkina, Z. M.; Avetisian, L. R.; Chernukha, M. Y.; et al. Disruption of bacterial biofilms using recombinant dispersin B. *Microbiology* 2015, 84, 498-501. DOI: 10.1134/S0026261715040062
80. Fagerlund, A.; Langsrud, S.; Heir, E.; Mikkelsen, M. I.; Moretro, T. Biofilm matrix composition affects the susceptibility of food associated staphylococci to cleaning and disinfection agents. *Front. Microbiol.* 2016, 7, 856. DOI: 10.3389/fmicb.2016.00856
81. Frank, K. L.; Patel, R. Poly-N-acetylglucosamine is not a major component of the extracellular matrix in biofilms formed by icaADBC-positive *Staphylococcus lugdunensis* isolates. *Infect. Immun.* 2007, 75, 4728-4742. DOI: 10.1128/IAI.00640-07
82. Kaplan, J. B.; Jabbouri, S.; Sadovskaya, I. Extracellular DNA-dependent biofilm formation by *Staphylococcus epidermidis* RP62A in response to subminimal inhibitory concentrations of antibiotics. *Res. Microbiol.* 2011, 162, 535-541. DOI: 10.1016/j.resmic.2011.03.008
83. Loughran, A. J.; Atwood, D. N.; Anthony, A. C.; Harik, N. S.; Spencer, H. J.; Beenken, K. E.; Smeltzer, M. S. Impact of individual extracellular proteases on *Staphylococcus aureus* biofilm formation in diverse clinical isolates and their isogenic *sarA* mutants. *Microbiologyopen* 2014, 3, 897-909. DOI: 10.1002/mbo3.214
84. Piarali, S.; Marlinghaus, L.; Viebahn, R.; Lewis, H.; Ryadnov, M. G.; Groll, J.; Salber, J.; Roy, I. Activated polyhydroxyalkanoate meshes prevent bacterial adhesion and biofilm development in regenerative medicine applications. *Front. Bioeng. Biotechnol.* 2020, 8, 442. DOI: 10.3389/fbioe.2020.00442
85. Sadovskaya, I.; Chaignon, P.; Kogan, G.; Chokr, A.; Vinogradov, E.; Jabbouri, S. Carbohydrate-containing components of biofilms produced in vitro by some staphylococcal strains related to orthopaedic prosthesis infections. *FEMS Immunol. Med. Microbiol.* 2006, 47, 75-82. DOI: 10.1111/j.1574-695X.2006.00068.x
86. Lee, J. H.; Kaplan, J. B.; Lee, W. Y. Microfluidic devices for studying growth and detachment of *Staphylococcus epidermidis* biofilms. *Biomed. Microdevices* 2008, 10, 489-498. DOI: 10.1007/s10544-007-9157-0
87. Itoh, Y.; Wang, X.; Hinnebusch, B. J.; Preston, J. F., 3rd; Romeo, T. Depolymerization of beta-1,6-N-acetyl-D-glucosamine disrupts the integrity of diverse bacterial biofilms. *J. Bacteriol.* 2005, 187, 382-387. DOI: 10.1128/JB.187.1.382-387.2005
88. Ragunath, C.; Shanmugam, M.; Bendaoud, M.; Kaplan, J. B.; Ramasubbu, N. Effect of a biofilm-degrading enzyme from an oral pathogen in transgenic tobacco on the pathogenicity of *Pectobacterium carotovorum* subsp. *carotovorum*. *Plant Pathol.* 2012, 61, 346-354. DOI: 10.1111/j.1365-3059.2011.02509.x
89. Wen, J.; Wang, Z.; Du, X.; Liu, R.; Wang, J. Antibiofilm effects of extracellular matrix degradative agents on the biofilm of different strains of multi-drug resistant *Corynebacterium striatum*. *Ann. Clin. Microbiol. Antimicrob.* 2022, 21, 53. DOI: 10.1186/s12941-022-00546-y
90. Poilvache, H.; Ruiz-Sorribas, A.; Cornu, O.; Van Bambeke, F. In vitro study of the synergistic effect of an enzyme cocktail and antibiotics against biofilms in a prosthetic joint infection model. *Antimicrob. Agents Chemother.* 2021, 65. DOI: 10.1128/AAC.01699-20
91. Waryah, C. B.; Wells, K.; Ulluwishewa, D.; Chen-Tan, N.; Gogoi-Tiwari, J.; Ravensdale, J.; Costantino, P.; Gökçen, A.; Vilcinskis, A.; Wiesner, J.; Mukkur, T. In vitro antimicrobial efficacy of tobramycin against *Staphylococcus aureus* biofilms in combination with or without DNase I and/or dispersin B: a preliminary investigation. *Microb. Drug Resist.* 2017, 23, 384-390. DOI: 10.1089/mdr.2016.0100
92. Chiba, A.; Seki, M.; Suzuki, Y.; Kinjo, Y.; Mizunoe, Y.; Sugimoto, S. *Staphylococcus aureus* utilizes environmental RNA as a building material in specific polysaccharide-dependent biofilms. *NPJ Biofilms Microbiomes* 2022, 8, 17. DOI: 10.1038/s41522-022-00278-z
93. Hagen, C. R. M.; Singh, A.; Weese, J. S.; Marshall, Q.; Zur Linden, A.; Gibson, T. W. G. In vitro elution of amikacin and dispersin B from a polymer hydrogel. *Vet. Surg.* 2020, 49, 1035-1042. DOI: 10.1111/vsu.13421
94. Marcano, A.; Ba, O.; Thebault, P.; Cretois, R.; Marais, S.; Duncan, A. C. Elucidation of innovative antibiofilm materials. *Colloids Surf. B Biointerfaces* 2015, 136, 56-63. DOI: 10.1016/j.colsurfb.2015.08.007
95. Marcano, A.; Bou Haidar, N.; Marais, S.; Valleton, J. M.; Duncan, A. C. Designing biodegradable PHA-based 3D scaffolds with antibiofilm properties for wound dressings: optimization of the microstructure/nanostructure. *ACS Biomater. Sci. Eng.* 2017, 3, 3654-3661. DOI: 10.1021/acsbomaterials.7b00552
96. Pavlukhina, S. V.; Kaplan, J. B.; Xu, L.; Chang, W.; Yu, X.; Madhyastha, S.; Yakandawala, N.; Mentbayeva, A.; Khan, B.; Sukhishvili, S. A. Noneluting enzymatic antibiofilm coatings. *ACS Appl. Mater. Interfaces* 2012, 4, 4708-4716. DOI: 10.1021/am3010847
97. Camporeale, G.; Moreno-Couranjou, M.; Bonot, S.; Mauchauffé, R.; Boscher, N. D.; Bebrone, C.; Van de Weert, C.; Cauchie, H.-M.; Favia, P.; Choquet, P. Atmospheric-pressure plasma deposited epoxy-rich thin films as platforms for biomolecule immobilization—application for anti-biofouling and xenobiotic-degrading surfaces. *Plasma Process. Polym.* 2015, 12, 1208-1219. DOI: 10.1002/ppap.201400206
98. Czuba, U.; Quintana, R.; De Pauw-Gillet, M. C.; Bourguignon, M.; Moreno-Couranjou, M.; Alexandre, M.; Detrembleur, C.; Choquet, P. Atmospheric plasma deposition of methacrylate layers containing

- catechol/quinone groups: an alternative to polydopamine bioconjugation for biomedical applications. *Adv. Healthc. Mater.* 2018, 7, e1701059. DOI: 10.1002/adhm.201701059
99. Faure, E.; Falentin-Daudré, C.; Svaldo Lanero, T.; Vreuls, C.; Zocchi, G.; Van De Weerd, C.; Martial, J.; Jérôme, C.; Duwez, A.-S.; Christophe Detrembleur, C. Functional nanogels as platforms for imparting antibacterial, antibiofilm, and antiadhesion activities to stainless steel. *Adv. Funct. Mater.* 2012, 22, 5271-5282. DOI: 10.1002/adfm.201201106
 100. Nileback, L.; Widhe, M.; Seijsing, J.; Bysell, H.; Sharma, P. K.; Hedhammar, M. Bioactive silk coatings reduce the adhesion of *Staphylococcus aureus* while supporting growth of osteoblast-like cells. *ACS Appl. Mater. Interfaces* 2019, 11, 24999-25007. DOI: 10.1021/acsami.9b05531
 101. Seijsing, F.; Nileback, L.; Ohman, O.; Pasupuleti, R.; Stahl, C.; Seijsing, J.; Hedhammar, M. Recombinant spider silk coatings functionalized with enzymes targeting bacteria and biofilms. *Microbiologyopen* 2020, 9, e993. DOI: 10.1002/mbo3.993
 102. Lu, T. K.; Collins, J. J. Dispersing biofilms with engineered enzymatic bacteriophage. *Proc. Natl. Acad. Sci. U S A* 2007, 104, 11197-11202. DOI: 10.1073/pnas.0704624104
 103. Schmerer, M.; Molineux, I. J.; Ally, D.; Tyerman, J.; Cecchini, N.; Bull, J. J. Challenges in predicting the evolutionary maintenance of a phage transgene. *J. Biol. Eng.* 2014, 8, 21. DOI: 10.1186/1754-1611-8-21
 104. Kaplan, J. B.; Mlynek, K. D.; Hettiarachchi, H.; Alamneh, Y. A.; Biggemann, L.; Zurawski, D. V.; Black, C. C.; Bane, C. E.; Kim, R. K.; Granick, M. S. Extracellular polymeric substance (EPS)-degrading enzymes reduce staphylococcal surface attachment and biocide resistance on pig skin in vivo. *PLoS One* 2018, 13, e0205526. DOI: 10.1371/journal.pone.0205526
 105. Serrera, A.; del Pozo, J. L.; Martinez, A.; Alonso, M.; Gonzalez, R.; Leiva, J.; Vergara, M.; Lasa, I. Dispersin B therapy of *Staphylococcus aureus* experimental port-related bloodstream infection. 17th European Congress of Clinical Microbiology and Infectious Disease, Munich, Germany; 2007, Poster P1786.
 106. Nait Chabane, Y.; Marti, S.; Rihouey, C.; Alexandre, S.; Hardouin, J.; Lesouhaitier, O.; Vila, J.; Kaplan, J. B.; Jouenne, T.; De, E. Characterisation of pellicles formed by *Acinetobacter baumannii* at the air-liquid interface. *PLoS One* 2014, 9, e111660. DOI: 10.1371/journal.pone.0111660
 107. Bossé, J. T.; Sinha, S.; Li, M. S.; O'Dwyer, C. A.; Nash, J. H.; Rycroft, A. N.; Kroll, J. S.; Langford, P. R. Regulation of pga operon expression and biofilm formation in *Actinobacillus pleuropneumoniae* by sigmaE and H-NS. *J. Bacteriol.* 2010, 192, 2414-2423. DOI: 10.1128/JB.01513-09
 108. Grasteau, A.; Tremblay, Y. D.; Labrie, J.; Jacques, M. Novel genes associated with biofilm formation of *Actinobacillus pleuropneumoniae*. *Vet. Microbiol.* 2011, 153, 134-143. DOI: 10.1016/j.vetmic.2011.03.029
 109. Izano, E. A.; Sadvovskaya, I.; Vinogradov, E.; Mulks, M. H.; Velliyagounder, K.; Ragunath, C.; Kher, W. B.; Ramasubbu, N.; Jabbouri, S.; Perry, M. B.; Kaplan, J. B. Poly-N-acetylglucosamine mediates biofilm formation and antibiotic resistance in *Actinobacillus pleuropneumoniae*. *Microb. Pathog.* 2007, 43, 1-9. DOI: 10.1016/j.micpath.2007.02.004
 110. Labrie, J.; Pelletier-Jacques, G.; Deslandes, V.; Ramjeet, M.; Auger, E.; Nash, J. H.; Jacques, M. Effects of growth conditions on biofilm formation by *Actinobacillus pleuropneumoniae*. *Vet. Res.* 2010, 41, 3. DOI: 10.1051/vetres/2009051
 111. Li, Y.; Cao, S.; Zhang, L.; Yuan, J.; Lau, G. W.; Wen, Y.; Wu, R.; Zhao, Q.; Huang, X.; Yan, Q.; et al. Absence of TolC impairs biofilm formation in *Actinobacillus pleuropneumoniae* by reducing initial attachment. *PLoS One* 2016, 11, e0163364. DOI: 10.1371/journal.pone.0163364
 112. Tremblay, Y. D.; Levesque, C.; Segers, R. P.; Jacques, M. Method to grow *Actinobacillus pleuropneumoniae* biofilm on a biotic surface. *BMC Vet. Res.* 2013, 9, 213. DOI: 10.1186/1746-6148-9-213
 113. Zhang, Q.; Peng, L.; Han, W.; Chen, H.; Tang, H.; Chen, X.; Langford, P. R.; Huang, Q.; Zhou, R.; Li, L. The morphology and metabolic changes of *Actinobacillus pleuropneumoniae* during its growth as a biofilm. *Vet. Res.* 2023, 54, 42. DOI: 10.1186/s13567-023-01173-x
 114. Dashiff, A.; Kadouri, D. E. Predation of oral pathogens by *Bdellovibrio bacteriovorus* 109J. *Mol. Oral Microbiol.* 2011, 26, 19-34. DOI: 10.1111/j.2041-1014.2010.00592.x
 115. Izano, E. A.; Sadvovskaya, I.; Wang, H.; Vinogradov, E.; Ragunath, C.; Ramasubbu, N.; Jabbouri, S.; Perry, M. B.; Kaplan, J. B. Poly-N-acetylglucosamine mediates biofilm formation and detergent resistance in *Aggregatibacter actinomycetemcomitans*. *Microb. Pathog.* 2008, 44, 52-60. DOI: 10.1016/j.micpath.2007.08.004
 116. Venketaraman, V.; Lin, A. K.; Le, A.; Kachlany, S. C.; Connell, N. D.; Kaplan, J. B. Both leukotoxin and poly-N-acetylglucosamine surface polysaccharide protect *Aggregatibacter actinomycetemcomitans* cells from macrophage killing. *Microb. Pathog.* 2008, 45, 173-180. DOI: 10.1016/j.micpath.2008.05.007
 117. Fullen, A. R.; Gutierrez-Ferman, J. L.; Yount, K. S.; Love, C. F.; Choi, H. G.; Vargas, M. A.; Raju, D.; Corps, K. N.; Howell, P. L.; Dubey, P.; Deora, R. Bps polysaccharide of *Bordetella pertussis* resists antimicrobial peptides by functioning as a dual surface shield and decoy and converts *Escherichia coli* into a respiratory pathogen. *PLoS Pathog.* 2022, 18, e1010764. DOI: 10.1371/journal.ppat.1010764
 118. Parise, G.; Mishra, M.; Itoh, Y.; Romeo, T.; Deora, R. Role of a putative polysaccharide locus in *Bordetella* biofilm development. *J. Bacteriol.* 2007, 189, 750-760. DOI: 10.1128/JB.00953-06

119. Messiaen, A. S.; Nelis, H.; Coenye, T. Investigating the role of matrix components in protection of *Burkholderia cepacia* complex biofilms against tobramycin. *J. Cyst. Fibros.* 2014, 13, 56-62. DOI: 10.1016/j.jcf.2013.07.004
120. Siebert, C.; Villers, C.; Pavlou, G.; Touquet, B.; Yakandawala, N.; Tardieux, I.; Renesto, P. *Francisella novicida* and *F. philomiragia* biofilm features conditioning fitness in spring water and in presence of antibiotics. *PLoS ONE* 2020, 15, e0228591. DOI: 10.1371/journal.pone.0228591
121. Perez-Mendoza, D.; Coulthurst, S. J.; Sanjuan, J.; Salmond, G. P. C. N-Acetylglucosamine-dependent biofilm formation in *Pectobacterium atrosepticum* is cryptic and activated by elevated c-di-GMP levels. *Microbiology (Reading)* 2011, 157, 3340-3348. DOI: 10.1099/mic.0.050450-0
122. Nicholson, T. L.; Shore, S. M.; Smith, T. C.; Frana, T. S. Livestock-associated methicillin-resistant *Staphylococcus aureus* (LA-MRSA) isolates of swine origin form robust biofilms. *PLoS ONE* 2013, 8, e73376. DOI: 10.1371/journal.pone.0073376
123. Turk, R.; Singh, A.; Rousseau, J.; Weese, J. S. In vitro evaluation of DispersinB on methicillin-resistant *Staphylococcus pseudintermedius* biofilm. *Vet. Microbiol.* 2013, 166, 576-579. DOI: 10.1016/j.vetmic.2013.07.011
124. Rmaile, A.; Ward, M. T.; Aspiras, M.; Stoodley, P. Disruption of dental biofilms by matrix-degrading enzymes. British Society for Oral and Dental Research BSODR, 2013, Conference paper.
125. van Dissel, D.; Willemse, J.; Zacchetti, B.; Claessen, D.; Pier, G. B.; van Wezel, G. P. Production of poly-beta-1,6-N-acetylglucosamine by MatAB is required for hyphal aggregation and hydrophilic surface adhesion by *Streptomyces*. *Microb. Cell* 2018, 5, 269-279. DOI: 10.15698/mic.2018.06.635
126. Irie, Y.; Preston, A.; Yuk, M. H. Expression of the primary carbohydrate component of the *Bordetella bronchiseptica* biofilm matrix is dependent on growth phase but independent of Bvg regulation. *J. Bacteriol.* 2006, 188, 6680-6687. DOI: 10.1128/JB.00605-06
127. Kaplan, J. B. Biofilm dispersal: mechanisms, clinical implications, and potential therapeutic uses. *J. Dent. Res.* 2010, 89, 205-218. DOI: 10.1177/0022034509359403
128. Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Meng, E. C.; Couch, G. S.; Croll, T. I.; Morris, J. H.; Ferrin, T. E. UCSF ChimeraX: Structure visualization for researchers, educators, and developers. *Protein Sci.* 2021 30, 70-82. DOI: 10.1002/pro.3943

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.